{"matching_results": 28082, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1290, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 987}, {"key": "negative", "matching_results": 292}, {"key": "neutral", "matching_results": 10}]}]}, {"key": "tickerreport.com", "matching_results": 686, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 592}, {"key": "negative", "matching_results": 92}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "watchlistnews.com", "matching_results": 661, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 481}, {"key": "negative", "matching_results": 180}]}]}, {"key": "dailypolitical.com", "matching_results": 639, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 542}, {"key": "negative", "matching_results": 97}]}]}, {"key": "freelancer.com.co", "matching_results": 625, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 573}, {"key": "negative", "matching_results": 51}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "wkrb13.com", "matching_results": 609, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 479}, {"key": "negative", "matching_results": 130}]}]}, {"key": "theolympiareport.com", "matching_results": 563, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 376}, {"key": "negative", "matching_results": 187}]}]}, {"key": "zolmax.com", "matching_results": 533, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 405}, {"key": "negative", "matching_results": 128}]}]}, {"key": "thelincolnianonline.com", "matching_results": 501, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 359}, {"key": "negative", "matching_results": 142}]}]}, {"key": "marketscreener.com", "matching_results": 452, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 307}, {"key": "negative", "matching_results": 143}, {"key": "neutral", "matching_results": 2}]}]}]}], "results": [{"id": "NA2wVp6Clbb86QlDNsaRM6_Qohxopnpx6_MKVJIpGyh2mcXz0pgTaTWvGQ6G146u", "result_metadata": {"score": 36.8682}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.896398, "label": "/finance/investing"}, {"score": 0.896398, "label": "/finance/investing/beginning investing"}, {"score": 0.88517, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "HBK Investments LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995975, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.840093, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.191512, "count": 1}]}, "crawl_date": "2018-11-22T14:19:11Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45347125-hbk-investments-lp-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-22T14:01:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.988692, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.910266, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.83781, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.749921, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.679365, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.679365, "type": "Quantity"}], "sentiment": {"document": {"score": -0.418973, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YES : Shire Plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945303, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.805651, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Hedge fund", "relevance": 0.778056, "dbpedia_resource": "http://dbpedia.org/resource/Hedge_fund"}, {"text": "Investment", "relevance": 0.727384, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Collective investment scheme", "relevance": 0.687831, "dbpedia_resource": "http://dbpedia.org/resource/Collective_investment_scheme"}, {"text": "Security", "relevance": 0.670192, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Mutual fund", "relevance": 0.64546, "dbpedia_resource": "http://dbpedia.org/resource/Mutual_fund"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.643202, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Name", "relevance": 0.641726, "dbpedia_resource": "http://dbpedia.org/resource/Name"}], "categories": [{"score": 0.810546, "label": "/finance/investing/funds"}, {"score": 0.803437, "label": "/real estate/buying and selling homes"}, {"score": 0.79765, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [302, 307], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [280, 283], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.828157, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.697913, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.647805, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.636224, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624045, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.616033, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.74856, "label": "negative"}, "relevance": 0.595763, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.589863, "count": 1}, {"text": "offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589451, "count": 1}, {"text": "disclosure", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.582135, "count": 2}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575932, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.57215, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571749, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569448, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565923, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.565396, "count": 1}, {"text": "funds", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.561557, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560195, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.558148, "count": 5}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.555216, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.555034, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554596, "count": 1}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554313, "count": 2}, {"text": "PERSON", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.549906, "count": 1}, {"text": "Interests", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.543737, "count": 1}, {"text": "HBK Investments L.P.", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.542798, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542153, "count": 1}, {"text": "behalf", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.537989, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.537055, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535274, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.532248, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531943, "count": 1}, {"text": "November", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531839, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529103, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525772, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524157, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522823, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522782, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.521793, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51644, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515011, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512486, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.511867, "count": 1}, {"text": "Code", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.508848, "count": 1}, {"text": "identity of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504983, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.503069, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.500146, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496035, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.48919, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.485661, "count": 1}]}, "extracted_metadata": {"sha1": "92023076aaaaac772dd3b842252b8442ad89f321", "filename": "1542896351600.zip-1d96daf0b6f49ab17fdf6f6786472904.xml", "file_type": "json"}, "title": "HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: News"}, {"id": "UXOB8PA_YO-S2x9gOAFXFv_zPNgipbSkUXhp0SDCHyWkY4_j1DKnTgY5TkMjnb5P", "result_metadata": {"score": 36.500355}, "author": "Zacks.com", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Shire-Takeda Deal", "keywords": [{"text": "Shire-Takeda Deal"}]}, "sentence": "Shire-Takeda Deal Gets Phase I Conditional European Approval - Nasdaq.com", "object": {"text": "Phase I Conditional European Approval", "keywords": [{"text": "European Approval"}, {"text": "Phase"}]}, "action": {"verb": {"text": "Gets", "tense": "present"}, "text": "Gets", "normalized": "Gets"}}], "concepts": [], "categories": [{"score": 0.657961, "label": "/business and industrial/construction"}, {"score": 0.60331, "label": "/law, govt and politics"}, {"score": 0.602295, "label": "/law, govt and politics/government/government contracting and procurement"}], "relations": [{"type": "managerOf", "sentence": "Shire-Takeda Deal Gets Phase I Conditional European Approval - Nasdaq.com", "score": 0.310665, "arguments": [{"text": "I", "location": [29, 30], "entities": [{"type": "Person", "text": "I"}]}, {"text": "Conditional European Approval", "location": [31, 60], "entities": [{"type": "Organization", "text": "Conditional European Approval"}]}]}], "keywords": [{"text": "Shire-Takeda Deal Gets Phase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998737, "count": 1}, {"text": "Nasdaq", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.663046, "count": 1}, {"text": "com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.636052, "count": 1}, {"text": "Conditional European Approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.430232, "count": 1}]}, "crawl_date": "2018-11-21T18:31:28Z", "url": "https://www.nasdaq.com/article/shire-takeda-deal-gets-phase-i-conditional-european-approval-cm1059514", "host": "nasdaq.com", "text": "Shutterstock photo Shire Plc SHPG announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co.", "main_image_url": "https://www.nasdaq.com/images/dreamit.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T09:36:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc Price", "relevance": 0.854442, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.84252, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.32439, "label": "negative"}, "text": "Merck & Co", "relevance": 0.817218, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.816551, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.749211, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.741323, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 2, "sentiment": {"score": -0.498811, "label": "negative"}, "text": "Shire", "relevance": 0.724503, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc SHPG", "relevance": 0.715996, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.661696, "type": "Person"}, {"count": 2, "sentiment": {"score": 0.394253, "label": "positive"}, "text": "Bristol-Myers Squibb Company BMY", "relevance": 0.58012, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.532349, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.498811, "label": "negative"}, "text": "European Commission", "relevance": 0.491722, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers", "relevance": 0.417333, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Union", "relevance": 0.399841, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson JNJ", "relevance": 0.377612, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.35727, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson", "relevance": 0.337783, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Court", "relevance": 0.336552, "type": "Organization", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}, {"count": 1, "sentiment": {"score": 0.554136, "label": "positive"}, "text": "marijuana", "relevance": 0.327895, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRK", "relevance": 0.322223, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc", "relevance": 0.297072, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "four quarters", "relevance": 0.288285, "type": "Quantity"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "60 days", "relevance": 0.288285, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "36%", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$20.2 billion", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$6.7 billion", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "30 Days", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.99%", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.62", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.82", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.84", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.08", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.27", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.34", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.63", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.71", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$8.14", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$8.16", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$8.61", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$8.66", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.65%", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10.2%", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "14.5%", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.96%", "relevance": 0.288285, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62", "relevance": 0.288285, "type": "Quantity"}], "sentiment": {"document": {"score": 0.601815, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Shire Plc SHPG", "keywords": [{"text": "Plc SHPG"}], "entities": [{"type": "Company", "text": "Shire Plc SHPG"}]}, "sentence": " Shire Plc SHPG announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co.", "object": {"text": "that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co", "keywords": [{"text": "Union antitrust regulators"}, {"text": "conditional approval"}, {"text": "Takeda Pharmaceutical"}, {"text": "phase"}], "entities": [{"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the European Union antitrust regulators", "keywords": [{"text": "Union antitrust regulators"}, {"text": "European"}], "entities": [{"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " Shire Plc SHPG announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co.", "object": {"text": "I conditional approval", "keywords": [{"text": "conditional approval"}]}, "action": {"verb": {"text": "grant", "tense": "past"}, "text": "have granted", "normalized": "have grant"}}, {"subject": {"text": "The European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "approved the deal subject to Shire selling an inflammatory bowel disease treatment", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "deal subject"}, {"text": "Shire"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "Takeda-marketed product Entyvio"}, {"text": "deal subject"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "has approved", "normalized": "have approve"}}, {"subject": {"text": "an inflammatory bowel disease treatment", "keywords": [{"text": "inflammatory bowel disease"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "SHP647 that could compete with a Takeda-marketed product Entyvio", "keywords": [{"text": "Takeda-marketed product Entyvio"}]}, "action": {"verb": {"text": "call", "tense": "past"}, "text": "called", "normalized": "call"}}, {"subject": {"text": "an inflammatory bowel disease treatment, called SHP647", "keywords": [{"text": "inflammatory bowel disease"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "with a Takeda-marketed product Entyvio (vedolizumab)", "keywords": [{"text": "Takeda-marketed product Entyvio"}, {"text": "vedolizumab"}]}, "action": {"verb": {"text": "compete", "tense": "future"}, "text": "could compete", "normalized": "could compete"}}, {"subject": {"text": "SHP647", "keywords": [{"text": "SHP647"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "hit", "tense": "present"}, "text": "hits", "normalized": "hit"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire.", "object": {"text": "that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire", "keywords": [{"text": "final regulatory approval"}, {"text": "European Commission"}, {"text": "clearance"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "state", "tense": "past"}, "text": "stated", "normalized": "state"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda had announced the acquisition in May 2018.", "object": {"text": "announced the acquisition", "keywords": [{"text": "acquisition"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda had announced the acquisition in May 2018.", "object": {"text": "the acquisition", "keywords": [{"text": "acquisition"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "had announced", "normalized": "have announce"}}, {"subject": {"text": "The acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " The acquisition is subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court.", "object": {"text": "subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court", "keywords": [{"text": "Scheme Document"}, {"text": "certain other conditions"}, {"text": "Takeda"}, {"text": "shareholders"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "Court", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court", "keywords": [{"text": "Scheme Document"}, {"text": "Takeda"}, {"text": "shareholders"}, {"text": "sanction"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "Court", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}]}, "sentence": " The acquisition is subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court.", "object": {"text": "certain other conditions", "keywords": [{"text": "certain other conditions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the other conditions", "keywords": [{"text": "conditions"}]}, "sentence": " The acquisition is subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Shire and Takeda", "keywords": [{"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}, {"type": "Person", "text": "Takeda"}]}, "sentence": " Assuming these conditions are met, Shire and Takeda confirmed that the acquisition will close on Jan 8, 2019.", "object": {"text": "that the acquisition will close on Jan 8", "keywords": [{"text": "acquisition"}, {"text": "Jan"}]}, "action": {"verb": {"text": "confirm", "tense": "past"}, "text": "confirmed", "normalized": "confirm"}}, {"subject": {"text": "the acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " Assuming these conditions are met, Shire and Takeda confirmed that the acquisition will close on Jan 8, 2019.", "action": {"verb": {"text": "close", "tense": "future"}, "text": "will close", "normalized": "will close"}}, {"subject": {"text": "Both the companies", "keywords": [{"text": "companies"}]}, "sentence": " Both the companies are leaders in their therapeutic areas and also have an attractive geographic footprint.", "object": {"text": "an attractive geographic footprint", "keywords": [{"text": "attractive geographic footprint"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "the combined group", "keywords": [{"text": "group"}]}, "sentence": " Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world", "object": {"text": "better positioned to deliver highly-innovative medicines and transformative care", "keywords": [{"text": "transformative care"}, {"text": "highly-innovative medicines"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "the combined group", "keywords": [{"text": "group"}]}, "sentence": " Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world", "object": {"text": "to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world", "keywords": [{"text": "transformative care"}, {"text": "brighter future"}, {"text": "highly-innovative medicines"}, {"text": "better health"}]}, "action": {"verb": {"text": "position", "tense": "future"}, "text": "positioned", "normalized": "position"}}, {"subject": {"text": "the combined group", "keywords": [{"text": "group"}]}, "sentence": " Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world", "object": {"text": "highly-innovative medicines and transformative care", "keywords": [{"text": "transformative care"}, {"text": "highly-innovative medicines"}]}, "action": {"verb": {"text": "deliver", "tense": "future"}, "text": "to deliver", "normalized": "to deliver"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 14.5% year to date, against the industry 's decline of 10.2%.", "object": {"text": "increased 14.5% year", "keywords": [{"text": "14.5"}], "entities": [{"type": "Quantity", "text": "14.5"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire is a Zacks Rank #3 (Hold) stock.", "object": {"text": "a Zacks Rank #3 (Hold) stock", "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Some better-ranked stocks worth considering", "keywords": [{"text": "better-ranked stocks"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company BMY"}]}, "sentence": " Some better-ranked stocks worth considering are Bristol-Myers Squibb Company BMY , Johnson and Johnson JNJ and Merck & Co.", "object": {"text": "Bristol-Myers Squibb Company BMY , Johnson and Johnson JNJ and Merck & Co", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Johnson JNJ"}, {"text": "Merck"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company BMY"}, {"type": "Person", "text": "Johnson"}, {"type": "Company", "text": "Johnson JNJ"}, {"type": "Company", "text": "Merck & Co", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Merck", "keywords": [{"text": "Merck"}], "entities": [{"type": "Company", "text": "Merck & Co", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "sentence": " While Bristol-Myers sports a Zacks Rank #1 (Strong Buy), J&J and Merck carry a Zacks Rank #2 (Buy).", "object": {"text": "a Zacks Rank #2 (Buy)", "keywords": [{"text": "Zacks Rank"}, {"text": "Buy"}]}, "action": {"verb": {"text": "carry", "tense": "present"}, "text": "carry", "normalized": "carry"}}, {"subject": {"text": "You"}, "sentence": " You can see the complete list of today's Zacks #1 Rank stocks here .", "object": {"text": "the complete list of today's Zacks #1 Rank stocks", "keywords": [{"text": "Zacks  Rank stocks"}, {"text": "complete list"}]}, "action": {"verb": {"text": "see", "tense": "future"}, "text": "can see", "normalized": "can see"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company delivered a positive earnings surprise in all of the trailing four quarters with average of 11.99%.", "object": {"text": "a positive earnings surprise", "keywords": [{"text": "positive earnings surprise"}]}, "action": {"verb": {"text": "deliver", "tense": "past"}, "text": "delivered", "normalized": "deliver"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company delivered a positive earnings surprise in all of the trailing four quarters with average of 3.96%.", "object": {"text": "a positive earnings surprise", "keywords": [{"text": "positive earnings surprise"}]}, "action": {"verb": {"text": "deliver", "tense": "past"}, "text": "delivered", "normalized": "deliver"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 36% year to date.", "object": {"text": "increased 36% year to date", "keywords": [{"text": "date"}], "entities": [{"type": "Quantity", "text": "36"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 36% year to date.", "object": {"text": "36% year", "entities": [{"type": "Quantity", "text": "36"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "have increased", "normalized": "have increase"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company delivered a positive earnings surprise in all of the trailing four quarters with average of 1.65%.", "object": {"text": "a positive earnings surprise", "keywords": [{"text": "positive earnings surprise"}]}, "action": {"verb": {"text": "deliver", "tense": "past"}, "text": "delivered", "normalized": "deliver"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 36% year to date.", "object": {"text": "increased 36% year to date", "keywords": [{"text": "date"}], "entities": [{"type": "Quantity", "text": "36"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 36% year to date.", "object": {"text": "36% year", "entities": [{"type": "Quantity", "text": "36"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "have increased", "normalized": "have increase"}}, {"subject": {"text": "for Stocks", "keywords": [{"text": "Stocks"}]}, "sentence": " Looking for Stocks with Skyrocketing Upside?", "object": {"text": "with Skyrocketing Upside", "keywords": [{"text": "Skyrocketing Upside"}]}, "action": {"verb": {"text": "Looking", "tense": "present"}, "text": "Looking", "normalized": "Looking"}}, {"subject": {"text": "Zacks", "keywords": [{"text": "Zacks"}]}, "sentence": " Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.", "object": {"text": "just released a Special Report on the booming investment opportunities of legal marijuana", "keywords": [{"text": "booming investment opportunities"}, {"text": "legal marijuana"}, {"text": "Special Report"}], "entities": [{"type": "Drug", "text": "marijuana"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Zacks", "keywords": [{"text": "Zacks"}]}, "sentence": " Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.", "object": {"text": "a Special Report on the booming investment opportunities of legal marijuana", "keywords": [{"text": "booming investment opportunities"}, {"text": "legal marijuana"}, {"text": "Special Report"}], "entities": [{"type": "Drug", "text": "marijuana"}]}, "action": {"verb": {"text": "release", "tense": "past"}, "text": "has just released", "normalized": "have just release"}}, {"subject": {"text": "by new referendums and legislation", "keywords": [{"text": "new referendums"}, {"text": "legislation"}]}, "sentence": " Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021.", "object": {"text": "this industry", "keywords": [{"text": "industry"}]}, "action": {"verb": {"text": "Ignited", "tense": "past"}, "text": "Ignited", "normalized": "Ignited"}}, {"subject": {"text": "Early investors", "keywords": [{"text": "Early investors"}]}, "sentence": " Early investors stand to make a killing, but you have to be ready to act and know just where to look.", "object": {"text": "to make a killing", "keywords": [{"text": "killing"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stand", "normalized": "stand"}}, {"subject": {"text": "Early investors", "keywords": [{"text": "Early investors"}]}, "sentence": " Early investors stand to make a killing, but you have to be ready to act and know just where to look.", "object": {"text": "a killing", "keywords": [{"text": "killing"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "stand to make", "normalized": "stand to make"}}, {"subject": {"text": "you"}, "sentence": " Early investors stand to make a killing, but you have to be ready to act and know just where to look.", "object": {"text": "just where to look"}, "action": {"verb": {"text": "know", "tense": "present"}, "text": "know", "normalized": "know"}}, {"subject": {"text": "we"}, "sentence": " See the pot trades we're targeting>>", "object": {"text": "the pot trades", "keywords": [{"text": "pot"}]}, "action": {"verb": {"text": "target", "tense": "present"}, "text": "targeting", "normalized": "target"}}, {"subject": {"text": "you"}, "sentence": " Today, you can download 7 Best Stocks for the Next 30 Days.", "object": {"text": "7 Best Stocks", "keywords": [{"text": "Best Stocks"}]}, "action": {"verb": {"text": "download", "tense": "future"}, "text": "can download", "normalized": "can download"}}, {"subject": {"text": "this"}, "sentence": " Click to get this free report", "object": {"text": "free report", "keywords": [{"text": "free report"}]}, "action": {"verb": {"text": "get", "tense": "future"}, "text": "to get", "normalized": "to get"}}, {"subject": {"text": "this article", "keywords": [{"text": "article"}]}, "sentence": " To read this article on Zacks.com click here.", "action": {"verb": {"text": "read", "tense": "future"}, "text": "To read", "normalized": "To read"}}], "concepts": [{"text": "Bristol-Myers Squibb", "relevance": 0.963426, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "European Union", "relevance": 0.704318, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "Clopidogrel", "relevance": 0.670154, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Paclitaxel", "relevance": 0.628243, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.616425, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}], "categories": [{"score": 0.897941, "label": "/finance/investing/stocks"}, {"score": 0.840025, "label": "/finance/investing/beginning investing"}, {"score": 0.771113, "label": "/business and industrial/company/merger and acquisition"}], "relations": [{"type": "agentOf", "sentence": "Shutterstock photo Shire Plc SHPG announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co. Ltd.'s $62-billion bid to acquire the former.", "score": 0.986517, "arguments": [{"text": "Shire Plc SHPG", "location": [19, 33], "entities": [{"type": "Person", "text": "Shire Plc SHPG"}]}, {"text": "announced", "location": [34, 43], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Takeda had announced the acquisition in May 2018.", "score": 0.889706, "arguments": [{"text": "Takeda", "location": [597, 603], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [608, 617], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "Takeda had announced the acquisition in May 2018.", "score": 0.667234, "arguments": [{"text": "Takeda", "location": [597, 603], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [622, 633], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Takeda had announced the acquisition in May 2018.", "score": 0.515256, "arguments": [{"text": "May 2018", "location": [637, 645], "entities": [{"type": "Date", "text": "May 2018"}]}, {"text": "announced", "location": [608, 617], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "timeOf", "sentence": "Takeda had announced the acquisition in May 2018.", "score": 0.914463, "arguments": [{"text": "May 2018", "location": [637, 645], "entities": [{"type": "Date", "text": "May 2018"}]}, {"text": "acquisition", "location": [622, 633], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "employedBy", "sentence": "The acquisition is subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court.", "score": 0.462823, "arguments": [{"text": "Shire", "location": [758, 763], "entities": [{"type": "Person", "text": "Shire Plc SHPG"}]}, {"text": "shareholders", "location": [742, 754], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Assuming these conditions are met, Shire and Takeda confirmed that the acquisition will close on Jan 8, 2019.", "score": 0.990937, "arguments": [{"text": "Takeda", "location": [954, 960], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "confirmed", "location": [961, 970], "entities": [{"type": "EventCommunication", "text": "confirmed"}]}]}, {"type": "timeOf", "sentence": "Assuming these conditions are met, Shire and Takeda confirmed that the acquisition will close on Jan 8, 2019.", "score": 0.596856, "arguments": [{"text": "2019", "location": [1013, 1017], "entities": [{"type": "Date", "text": "2019"}]}, {"text": "acquisition", "location": [980, 991], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "locatedAt", "sentence": "Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world Shares of the company have increased 14.5% year to date, against the industry 's decline of 10.2%.", "score": 0.59425, "arguments": [{"text": "patients", "location": [1291, 1299], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "world", "location": [1311, 1316], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world Shares of the company have increased 14.5% year to date, against the industry 's decline of 10.2%.", "score": 0.627602, "arguments": [{"text": "company", "location": [1331, 1338], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "world", "location": [1311, 1316], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Shire plc Price Shire plc Price | Shire plc Quote: Zacks Rank & Stocks to Consider Shire is a Zacks Rank #3 (Hold) stock.", "score": 0.687817, "arguments": [{"text": "Shire plc Price\nShire plc Price", "location": [1416, 1447], "entities": [{"type": "Person", "text": "Shire plc Price\nShire plc Price"}]}, {"text": "Quote", "location": [1460, 1465], "entities": [{"type": "EventCommunication", "text": "Quote"}]}]}, {"type": "employedBy", "sentence": "Shutterstock photo Shire Plc SHPG announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co. Ltd.'s $62-billion bid to acquire the former.", "score": 0.476079, "arguments": [{"text": "regulators", "location": [78, 88], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "European Union", "location": [53, 67], "entities": [{"type": "GeopoliticalEntity", "text": "European Union", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "While Bristol-Myers sports a Zacks Rank #1 (Strong Buy), J&J and Merck carry a Zacks Rank #2 (Buy).", "score": 0.630847, "arguments": [{"text": "Zacks Rank #1", "location": [1696, 1709], "entities": [{"type": "Person", "text": "Zacks Rank #1"}]}, {"text": "Strong Buy", "location": [1711, 1721], "entities": [{"type": "Organization", "text": "Strong Buy", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Merck's earnings per share estimates have increased from $4.27 to $4.34 for 2018 and from $4.63 to $4.71 for 2019 over the past 60 days.", "score": 0.569526, "arguments": [{"text": "Merck", "location": [2092, 2097], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$4.27", "location": [2149, 2154], "entities": [{"type": "Money", "text": "$4.27"}]}]}, {"type": "hasAttribute", "sentence": "Merck's earnings per share estimates have increased from $4.27 to $4.34 for 2018 and from $4.63 to $4.71 for 2019 over the past 60 days.", "score": 0.644751, "arguments": [{"text": "Merck", "location": [2092, 2097], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$4.34", "location": [2158, 2163], "entities": [{"type": "Money", "text": "$4.34"}]}]}, {"type": "agentOf", "sentence": "Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.", "score": 0.556697, "arguments": [{"text": "Zacks", "location": [2741, 2746], "entities": [{"type": "Person", "text": "Zacks Rank #3"}]}, {"text": "Report", "location": [2775, 2781], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here.", "score": 0.760847, "arguments": [{"text": "Zacks.com", "location": [3512, 3521], "entities": [{"type": "Person", "text": "Zacks Rank #3"}]}, {"text": "Report", "location": [3481, 3487], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "awardedTo", "sentence": "Today, you can download 7 Best Stocks for the Next 30 Days.", "score": 0.909052, "arguments": [{"text": "Best Stocks", "location": [3212, 3223], "entities": [{"type": "EntertainmentAward", "text": "Best Stocks"}]}, {"text": "you", "location": [3193, 3196], "entities": [{"type": "Person", "text": "you"}]}]}, {"type": "employedBy", "sentence": "Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here.", "score": 0.571124, "arguments": [{"text": "Johnson", "location": [3276, 3283], "entities": [{"type": "Person", "text": "Johnson"}]}, {"text": "& Johnson", "location": [3284, 3293], "entities": [{"type": "Organization", "text": "& Johnson", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here.", "score": 0.655421, "arguments": [{"text": "Merck & Co., Inc.", "location": [3391, 3408], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [3384, 3390], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "hasAttribute", "sentence": "The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "score": 0.855194, "arguments": [{"text": "Shire", "location": [265, 270], "entities": [{"type": "Person", "text": "Shire Plc SHPG"}]}, {"text": "bowel disease", "location": [295, 308], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}]}, {"type": "agentOf", "sentence": "The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "score": 0.594043, "arguments": [{"text": "Shire", "location": [265, 270], "entities": [{"type": "Person", "text": "Shire Plc SHPG"}]}, {"text": "called", "location": [320, 326], "entities": [{"type": "EventCommunication", "text": "called"}]}]}, {"type": "hasAttribute", "sentence": "The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "score": 0.709705, "arguments": [{"text": "SHP647", "location": [327, 333], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "bowel disease", "location": [295, 308], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}]}, {"type": "affectedBy", "sentence": "The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "score": 0.849124, "arguments": [{"text": "SHP647", "location": [327, 333], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "called", "location": [320, 326], "entities": [{"type": "EventCommunication", "text": "called"}]}]}, {"type": "agentOf", "sentence": "Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire.", "score": 0.946028, "arguments": [{"text": "Takeda", "location": [450, 456], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "stated", "location": [457, 463], "entities": [{"type": "EventCommunication", "text": "called"}]}]}, {"type": "agentOf", "sentence": "Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire.", "score": 0.643586, "arguments": [{"text": "its", "location": [571, 574], "entities": [{"type": "Organization", "text": "SHP647"}]}, {"text": "acquisition", "location": [575, 586], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire.", "score": 0.347349, "arguments": [{"text": "Shire", "location": [590, 595], "entities": [{"type": "Person", "text": "Shire Plc SHPG"}]}, {"text": "acquisition", "location": [575, 586], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Co. Ltd", "sentiment": {"score": 0.955904, "label": "positive"}, "relevance": 0.690794, "count": 1}, {"text": "Shire", "sentiment": {"score": 0.268329, "mixed": "1", "label": "positive"}, "relevance": 0.660208, "count": 3}, {"text": "European Union", "sentiment": {"score": 0.955904, "label": "positive"}, "relevance": 0.654985, "count": 1}, {"text": "Bristol-Myers Squibb Company BMY", "sentiment": {"score": 0.758166, "label": "positive"}, "relevance": 0.652112, "count": 1}, {"text": "Zacks Rank", "sentiment": {"score": 0.452294, "label": "positive"}, "relevance": 0.648171, "count": 4}, {"text": "acquisition of Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.636675, "count": 1}, {"text": "European Commission", "sentiment": {"score": -0.35261, "label": "negative"}, "relevance": 0.626104, "count": 2}, {"text": "Takeda", "sentiment": {"score": 0.561036, "mixed": "1", "label": "positive"}, "relevance": 0.621893, "count": 5}, {"text": "Shire plc Quote", "sentiment": {"score": 0.452294, "label": "positive"}, "relevance": 0.614606, "count": 1}, {"text": "better health", "sentiment": {"score": 0.993627, "label": "positive"}, "relevance": 0.603228, "count": 1}, {"text": "shareholders of Shire", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.573965, "count": 1}, {"text": "conditional approval", "sentiment": {"score": 0.955904, "label": "positive"}, "relevance": 0.570898, "count": 1}, {"text": "companies", "sentiment": {"score": 0.806758, "label": "positive"}, "relevance": 0.569461, "count": 1}, {"text": "company", "sentiment": {"score": 0.993627, "label": "positive"}, "relevance": 0.569461, "count": 4}, {"text": "conditions", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.558933, "count": 3}, {"text": "J&J", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558626, "count": 1}, {"text": "stock", "sentiment": {"score": 0.758166, "label": "positive"}, "relevance": 0.554354, "count": 1}, {"text": "Stocks", "sentiment": {"score": 0.452294, "label": "positive"}, "relevance": 0.554354, "count": 2}, {"text": "worth considering", "sentiment": {"score": 0.758166, "label": "positive"}, "relevance": 0.554349, "count": 1}, {"text": "Bristol-Myers sports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551858, "count": 1}, {"text": "complete list of today", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548887, "count": 1}, {"text": "acquisition", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.54545, "count": 3}, {"text": "inflammatory bowel disease treatment", "sentiment": {"score": -0.35261, "label": "negative"}, "relevance": 0.541242, "count": 1}, {"text": "stocks", "sentiment": {"score": 0.758166, "label": "positive"}, "relevance": 0.536315, "count": 1}, {"text": "Today", "sentiment": {"score": 0.758467, "label": "positive"}, "relevance": 0.531734, "count": 1}, {"text": "final regulatory approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531449, "count": 1}, {"text": "clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530973, "count": 1}, {"text": "deal", "sentiment": {"score": -0.35261, "label": "negative"}, "relevance": 0.530881, "count": 1}, {"text": "Bristol-Myers' earnings", "sentiment": {"score": -0.545955, "label": "negative"}, "relevance": 0.530758, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.863272, "label": "positive"}, "relevance": 0.530682, "count": 2}, {"text": "Special Report", "sentiment": {"score": 0.794147, "label": "positive"}, "relevance": 0.529355, "count": 1}, {"text": "Merck", "sentiment": {"score": 0.758166, "label": "positive"}, "relevance": 0.528399, "count": 2}, {"text": "group", "sentiment": {"score": 0.993627, "label": "positive"}, "relevance": 0.524047, "count": 1}, {"text": "satisfaction", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.522643, "count": 1}, {"text": "Early investors", "sentiment": {"score": -0.767999, "label": "negative"}, "relevance": 0.522154, "count": 1}, {"text": "brighter future", "sentiment": {"score": 0.993627, "label": "positive"}, "relevance": 0.520417, "count": 1}, {"text": "phase", "sentiment": {"score": 0.955904, "label": "positive"}, "relevance": 0.520159, "count": 1}, {"text": "views", "sentiment": {"score": 0.890908, "label": "positive"}, "relevance": 0.519513, "count": 2}, {"text": "market", "sentiment": {"score": -0.35261, "label": "negative"}, "relevance": 0.519503, "count": 1}, {"text": "receipt of approval", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.519413, "count": 1}, {"text": "opinions", "sentiment": {"score": 0.890908, "label": "positive"}, "relevance": 0.518429, "count": 1}, {"text": "waiver", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.518167, "count": 1}, {"text": "share estimates", "sentiment": {"score": -0.617161, "label": "negative"}, "relevance": 0.517971, "count": 3}, {"text": "SHP647", "sentiment": {"score": -0.35261, "label": "negative"}, "relevance": 0.516293, "count": 1}, {"text": "leaders", "sentiment": {"score": 0.806758, "label": "positive"}, "relevance": 0.514834, "count": 1}, {"text": "antitrust regulators", "sentiment": {"score": 0.955904, "label": "positive"}, "relevance": 0.512021, "count": 1}, {"text": "article", "sentiment": {"score": 0.890908, "label": "positive"}, "relevance": 0.511738, "count": 1}, {"text": "industry", "sentiment": {"score": 0.415129, "label": "positive"}, "relevance": 0.508818, "count": 1}, {"text": "legislation", "sentiment": {"score": 0.415129, "label": "positive"}, "relevance": 0.508816, "count": 1}, {"text": "year", "sentiment": {"score": 0.668565, "mixed": "1", "label": "positive"}, "relevance": 0.507634, "count": 3}]}, "extracted_metadata": {"sha1": "3e017841215ca411086ff5548359da778cb50d1c", "filename": "1542825088873.zip-1025fa40f1bfb91b740ac154e5901f1b.xml", "file_type": "json"}, "external_links": ["http://www.zacks.com/", "https://www.zacks.com/stocks/industry-rank/industry/medical-drugs-106", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=MRK&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-338822", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=JNJ&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-338822", "http://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-338822", "http://www.zacks.com/stock/news/338822/shire-takeda-deal-gets-phase-i-conditional-european-approval?cid=CS-NASDAQ-FT-338822", "https://www.zacks.com/stock/chart/SHPG/fundamental/price", "https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/381b?adid=ZCOM_ZU_MarijuanaReport_B_ANALYSTBLOG_IND_MARIJ2_112118&icid=EOAC-ANALYSTBLOG-tx-ZU112118", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=BMY&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-338822", "https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link", "https://www.zacks.com/stock/quote/SHPG", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=SHPG&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-338822"], "title": "Shire-Takeda Deal Gets Phase I Conditional European Approval - Nasdaq.com", "forum_title": "Bristol-Myers Squibb Company (BMY) Stock Report \u2013 NASDAQ.com - NASDAQ.com"}, {"id": "wOwwdWL1B6gmP54YeqSVsySoEStzUw8Bf0eG6HOu9cUTESSWBRrw15M_lIMNV5A7", "result_metadata": {"score": 36.35426}, "author": "Ankush Nikam", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Carcinoma HCC Treatment Growth Factors and Industry Analysis", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Cancer", "relevance": 0.9072, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}], "categories": [{"score": 0.895398, "label": "/health and fitness/disease/cancer"}, {"score": 0.781236, "label": "/business and industrial/paper industry"}, {"score": 0.759733, "label": "/business and industrial/war industry"}], "relations": [], "keywords": [{"text": "Industry Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570023, "count": 1}, {"text": "Hepatocellular Carcinoma HCC Treatment Growth Factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429977, "count": 1}]}, "crawl_date": "2018-11-21T19:55:31Z", "url": "https://www.findmarketresearch.org/2018/11/hepatocellular-carcinoma-hcc-treatment-market-growth-factors-and-industry-analysis-2016-2026/", "host": "findmarketresearch.org", "text": "Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T09:36:00+05:00", "enriched_text": {"entities": [{"count": 19, "sentiment": {"score": -0.426035, "label": "negative"}, "text": "Hepatocellular carcinoma", "relevance": 0.890009, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"count": 11, "sentiment": {"score": -0.612548, "label": "negative"}, "text": "HCC", "relevance": 0.278704, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "liver disease", "relevance": 0.0820437, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}}, {"count": 1, "sentiment": {"score": -0.525162, "label": "negative"}, "text": "biliary cirrhosis", "relevance": 0.0727103, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Primary biliary cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Primary_biliary_cirrhosis"}}, {"count": 1, "sentiment": {"score": -0.223199, "label": "negative"}, "text": "cirrhosis", "relevance": 0.0725672, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}, {"count": 1, "sentiment": {"score": -0.209731, "label": "negative"}, "text": "HCV", "relevance": 0.0719825, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause", "RiskFactor"], "name": "Virus", "dbpedia_resource": "http://dbpedia.org/resource/Virus"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer AG", "relevance": 0.0682511, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": -0.20346, "label": "negative"}, "text": "HCV", "relevance": 0.0672711, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}, {"count": 1, "sentiment": {"score": -0.704143, "label": "negative"}, "text": "U.S.", "relevance": 0.0645579, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.46489, "label": "negative"}, "text": "Novartis Pharmaceuticals", "relevance": 0.0611732, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": -0.569662, "label": "negative"}, "text": "principal", "relevance": 0.0610614, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva pharmaceutical Industries Ltd.", "relevance": 0.0603746, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.0596083, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.0594327, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.305367, "label": "negative"}, "text": "North America", "relevance": 0.0592128, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.0572761, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": -0.295954, "label": "negative"}, "text": "Middle East", "relevance": 0.0567549, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson Pvt", "relevance": 0.0555693, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgen Corporation", "relevance": 0.055183, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.535509, "label": "negative"}, "text": "metabolic syndrome", "relevance": 0.0542172, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Metabolic syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.0536521, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0.267702, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.0530715, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": -0.833957, "label": "negative"}, "text": "Asia", "relevance": 0.0530198, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0523404, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0.263121, "label": "positive"}, "text": "Western Europe", "relevance": 0.0516209, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": -0.833957, "label": "negative"}, "text": "Africa", "relevance": 0.0499925, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.048571, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": -0.333167, "label": "negative"}, "text": "Merck & Co., Inc.", "relevance": 0.0465486, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.046208, "type": "Company"}], "sentiment": {"document": {"score": -0.517199, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Hepatocellular carcinoma (HCC)", "keywords": [{"text": "Hepatocellular carcinoma"}, {"text": "HCC"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": "Hepatocellular carcinoma (HCC) is also known as malignant hepatoma.", "object": {"text": "also known as malignant hepatoma", "keywords": [{"text": "malignant hepatoma"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Hepatocellular carcinoma (HCC)", "keywords": [{"text": "Hepatocellular carcinoma"}, {"text": "HCC"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": "Hepatocellular carcinoma (HCC) is also known as malignant hepatoma.", "object": {"text": "as malignant hepatoma", "keywords": [{"text": "malignant hepatoma"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "is also known", "normalized": "be also know"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis.", "object": {"text": "the major malignancy of the liver", "keywords": [{"text": "major malignancy"}, {"text": "liver"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The cells of origin of HCC", "keywords": [{"text": "HCC"}, {"text": "cells"}, {"text": "origin"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation.", "object": {"text": "the hepatic stem cells", "keywords": [{"text": "hepatic stem cells"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The hepatic tumors", "keywords": [{"text": "hepatic tumors"}]}, "sentence": " The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases.", "object": {"text": "with local expansion", "keywords": [{"text": "local expansion"}]}, "action": {"verb": {"text": "proliferate", "tense": "present"}, "text": "proliferates", "normalized": "proliferate"}}, {"subject": {"text": "The uncommon hepatocellular carcinoma", "keywords": [{"text": "uncommon hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The uncommon hepatocellular carcinoma is anticipated to witness rise in incidence rate during the forecast period.", "object": {"text": "anticipated to witness rise in incidence rate", "keywords": [{"text": "incidence rate"}, {"text": "rise"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The uncommon hepatocellular carcinoma", "keywords": [{"text": "uncommon hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The uncommon hepatocellular carcinoma is anticipated to witness rise in incidence rate during the forecast period.", "object": {"text": "rise in incidence rate", "keywords": [{"text": "incidence rate"}, {"text": "rise"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is anticipated to witness", "normalized": "be anticipate to witness"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " HCC is currently expected to be the third leading cause of death worldwide.", "object": {"text": "currently expected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " HCC is currently expected to be the third leading cause of death worldwide.", "action": {"verb": {"text": "expect", "tense": "past"}, "text": "expected", "normalized": "expect"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " In the past, HCC generally occurred at an advanced stage of decompensated liver disease or cirrhosis.", "action": {"verb": {"text": "occur", "tense": "past"}, "text": "occurred", "normalized": "occur"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " In the past, HCC generally occurred at an advanced stage of decompensated liver disease or cirrhosis.", "object": {"text": "liver disease or cirrhosis", "keywords": [{"text": "liver disease"}, {"text": "cirrhosis"}], "entities": [{"type": "HealthCondition", "text": "liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}}]}, "action": {"verb": {"text": "decompensated", "tense": "past"}, "text": "decompensated", "normalized": "decompensated"}}, {"subject": {"text": "The technological advancements and the routine liver function tests", "keywords": [{"text": "routine liver function"}, {"text": "technological advancements"}]}, "sentence": " The technological advancements and the routine liver function tests are now resulting in the early detection of hepatocellular carcinoma.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "incidences of hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "incidences"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The increase in incidences of hepatocellular carcinoma associated with hepatitis C virus are expected to grow the hepatocellular carcinoma treatment market during the forecast period.", "object": {"text": "with hepatitis C virus", "keywords": [{"text": "hepatitis C virus"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S.", "keywords": [{"text": "intrahepatic bile duct"}, {"text": "incidence rate"}, {"text": "hepatic cancer"}, {"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2015.", "object": {"text": "approximately 39,230"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The risk factors", "keywords": [{"text": "risk factors"}]}, "sentence": " The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury.", "object": {"text": "with hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The risk factors associated with hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "risk factors"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury.", "object": {"text": "Hepatitis B virus", "keywords": [{"text": "Hepatitis B virus"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "cost effective treatment procedures", "keywords": [{"text": "cost effective treatment"}, {"text": "procedures"}]}, "sentence": " The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "few other factors", "keywords": [{"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "few other factors", "keywords": [{"text": "factors"}]}, "sentence": " The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "to keep up the growth of global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "predict", "tense": "past"}, "text": "predicted", "normalized": "predict"}}, {"subject": {"text": "few other factors", "keywords": [{"text": "factors"}]}, "sentence": " The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "up the growth of global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "keep", "tense": "future"}, "text": "predicted to keep", "normalized": "predict to keep"}}, {"subject": {"text": "side effects", "keywords": [{"text": "effects"}]}, "sentence": " However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "with the chemotherapy", "keywords": [{"text": "chemotherapy"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "high cost of treatment", "keywords": [{"text": "high cost"}, {"text": "treatment"}]}, "sentence": " However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "major restraints"}, {"text": "treatment market"}, {"text": "growth"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the global hepatocellular carcinoma (HCC) treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "HCC"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Based on application, the global hepatocellular carcinoma (HCC) treatment market is segmented into: Brachytherapy, Chemotherapy, Local Ablation Therapy; Based on end user type, the global hepatocellular carcinoma (HCC) treatment market is segmented into: Hospitals, Clinics, Cancer rehabilitation centers", "object": {"text": "segmented into: Hospitals, Clinics, Cancer rehabilitation centers", "keywords": [{"text": "Cancer rehabilitation centers"}, {"text": "Hospitals"}, {"text": "Clinics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Inventions in technologies for cancer treatment procedures", "keywords": [{"text": "cancer treatment procedures"}, {"text": "Inventions"}]}, "sentence": " Inventions in technologies for cancer treatment procedures are expected to launch into the market in the forecast period.", "object": {"text": "into the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "launch", "tense": "future"}, "text": "are expected to launch", "normalized": "be expect to launch"}}, {"subject": {"text": "Monoclonal antibodies and other immunological treatments", "keywords": [{"text": "Monoclonal antibodies"}, {"text": "immunological treatments"}]}, "sentence": " Monoclonal antibodies and other immunological treatments are generally known for their lesser side effects and better efficacy.", "object": {"text": "generally known"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Monoclonal antibodies and other immunological treatments", "keywords": [{"text": "Monoclonal antibodies"}, {"text": "immunological treatments"}]}, "sentence": " Monoclonal antibodies and other immunological treatments are generally known for their lesser side effects and better efficacy.", "object": {"text": "for their lesser side effects and better efficacy", "keywords": [{"text": "better efficacy"}, {"text": "lesser side effects"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "are generally known", "normalized": "be generally know"}}, {"subject": {"text": "the global Hepatocellular Carcinoma (HCC) treatment market", "keywords": [{"text": "global Hepatocellular Carcinoma"}, {"text": "HCC"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "object": {"text": "classified into regions", "keywords": [{"text": "regions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global Hepatocellular Carcinoma (HCC) treatment market", "keywords": [{"text": "global Hepatocellular Carcinoma"}, {"text": "HCC"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "object": {"text": "into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections", "keywords": [{"text": "hepatitis C virus"}, {"text": "Africa.Hepatitis B virus"}, {"text": "Middle East"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "HealthCondition", "text": "HCV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "is classified", "normalized": "be classify"}}, {"subject": {"text": "Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections", "keywords": [{"text": "hepatitis C virus"}, {"text": "Africa.Hepatitis B virus"}, {"text": "Middle East"}, {"text": "HBV"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "HealthCondition", "text": "HCV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "action": {"verb": {"text": "find", "tense": "past"}, "text": "are found to be", "normalized": "be find to be"}}, {"subject": {"text": "HBV) infection and hepatitis C virus (HCV) infections", "keywords": [{"text": "hepatitis C virus"}, {"text": "HBV"}, {"text": "HCV"}, {"text": "infection"}], "entities": [{"type": "HealthCondition", "text": "HCV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "object": {"text": "the most significant cause of hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "significant cause"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are found to be", "normalized": "be find to be"}}, {"subject": {"text": "Chronic HBV infection", "keywords": [{"text": "Chronic HBV infection"}]}, "sentence": " Chronic HBV infection is the principal cause of hepatocellular carcinoma in Asia and Africa.", "object": {"text": "the principal cause of hepatocellular carcinoma in Asia and Africa", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "principal cause"}, {"text": "Asia"}, {"text": "Africa"}], "entities": [{"type": "JobTitle", "text": "principal"}, {"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "HCV infection", "keywords": [{"text": "HCV infection"}]}, "sentence": " HCV infection is the principal cause of hepatocellular carcinoma in North America, Europe, and Japan.", "object": {"text": "the principal cause of hepatocellular carcinoma in North America, Europe, and Japan", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "principal cause"}, {"text": "North America"}, {"text": "Europe"}], "entities": [{"type": "JobTitle", "text": "principal"}, {"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The global hepatocellular carcinoma treatment market is expected to grow in future due to increasing investment by multinational companies in the cancer research.", "object": {"text": "in future"}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "Bayer AG", "keywords": [{"text": "Bayer AG"}], "entities": [{"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}]}, "sentence": " Bayer AG is one of the leading provider of hepatocellular carcinoma (HCC) treatment drugs.", "object": {"text": "one of the leading provider of hepatocellular carcinoma (HCC) treatment drugs", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "treatment drugs"}, {"text": "HCC"}, {"text": "provider"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Some of the key players in hepatocellular carcinoma treatment market", "keywords": [{"text": "hepatocellular carcinoma treatment"}, {"text": "key players"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt.", "object": {"text": "Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Novartis Pharmaceuticals"}, {"text": "Johnson Pvt"}, {"text": "Merck"}], "entities": [{"type": "Company", "text": "Novartis Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Johnson & Johnson Pvt"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the antiviral and oncology", "keywords": [{"text": "oncology"}]}, "sentence": " These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "object": {"text": "unmet medical needs", "keywords": [{"text": "unmet medical needs"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "to address", "normalized": "to address"}}], "concepts": [{"text": "Cirrhosis", "relevance": 0.987814, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Liver", "relevance": 0.915654, "dbpedia_resource": "http://dbpedia.org/resource/Liver"}, {"text": "Hepatitis C", "relevance": 0.912766, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Cancer", "relevance": 0.879223, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Hepatitis B", "relevance": 0.863342, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Hepatology", "relevance": 0.82542, "dbpedia_resource": "http://dbpedia.org/resource/Hepatology"}, {"text": "Hepatitis", "relevance": 0.700561, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Hepatocellular carcinoma", "relevance": 0.621748, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Bilirubin", "relevance": 0.567541, "dbpedia_resource": "http://dbpedia.org/resource/Bilirubin"}, {"text": "Oncology", "relevance": 0.462636, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Liver disease", "relevance": 0.440194, "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}, {"text": "Liver function tests", "relevance": 0.42019, "dbpedia_resource": "http://dbpedia.org/resource/Liver_function_tests"}, {"text": "Primary sclerosing cholangitis", "relevance": 0.400782, "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}, {"text": "Liver biopsy", "relevance": 0.390686, "dbpedia_resource": "http://dbpedia.org/resource/Liver_biopsy"}, {"text": "Hepatitis B virus", "relevance": 0.382565, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_virus"}, {"text": "Bile duct", "relevance": 0.381165, "dbpedia_resource": "http://dbpedia.org/resource/Bile_duct"}, {"text": "Bristol-Myers Squibb", "relevance": 0.378597, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Liver transplantation", "relevance": 0.356702, "dbpedia_resource": "http://dbpedia.org/resource/Liver_transplantation"}, {"text": "Hepatitis A", "relevance": 0.351319, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_A"}, {"text": "Interferon", "relevance": 0.346357, "dbpedia_resource": "http://dbpedia.org/resource/Interferon"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.344268, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Chemotherapy", "relevance": 0.340061, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Gastroenterology", "relevance": 0.327753, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Immune system", "relevance": 0.31594, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Alanine transaminase", "relevance": 0.304657, "dbpedia_resource": "http://dbpedia.org/resource/Alanine_transaminase"}, {"text": "Cholangiocarcinoma", "relevance": 0.303227, "dbpedia_resource": "http://dbpedia.org/resource/Cholangiocarcinoma"}, {"text": "Bile", "relevance": 0.294165, "dbpedia_resource": "http://dbpedia.org/resource/Bile"}, {"text": "Jade Ribbon Campaign", "relevance": 0.270667, "dbpedia_resource": "http://dbpedia.org/resource/Jade_Ribbon_Campaign"}, {"text": "Hepatitis C virus", "relevance": 0.269661, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}, {"text": "Paclitaxel", "relevance": 0.259627, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}, {"text": "Hepatic encephalopathy", "relevance": 0.258127, "dbpedia_resource": "http://dbpedia.org/resource/Hepatic_encephalopathy"}, {"text": "Alcoholic liver disease", "relevance": 0.256069, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholic_liver_disease"}, {"text": "Hepatic portal vein", "relevance": 0.246485, "dbpedia_resource": "http://dbpedia.org/resource/Hepatic_portal_vein"}, {"text": "Alcoholism", "relevance": 0.245395, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholism"}, {"text": "Cholestasis", "relevance": 0.245188, "dbpedia_resource": "http://dbpedia.org/resource/Cholestasis"}, {"text": "North America", "relevance": 0.244191, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Jaundice", "relevance": 0.243462, "dbpedia_resource": "http://dbpedia.org/resource/Jaundice"}, {"text": "Generic drug", "relevance": 0.243019, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Blood transfusion", "relevance": 0.241032, "dbpedia_resource": "http://dbpedia.org/resource/Blood_transfusion"}, {"text": "Primary biliary cirrhosis", "relevance": 0.239104, "dbpedia_resource": "http://dbpedia.org/resource/Primary_biliary_cirrhosis"}, {"text": "Clopidogrel", "relevance": 0.234513, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Wilson's disease", "relevance": 0.224541, "dbpedia_resource": "http://dbpedia.org/resource/Wilson's_disease"}, {"text": "Epidemiology", "relevance": 0.223231, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.222609, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Breast cancer", "relevance": 0.22249, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Gastrointestinal cancer", "relevance": 0.219982, "dbpedia_resource": "http://dbpedia.org/resource/Gastrointestinal_cancer"}, {"text": "Non-alcoholic fatty liver disease", "relevance": 0.214356, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}, {"text": "Carcinoma", "relevance": 0.214161, "dbpedia_resource": "http://dbpedia.org/resource/Carcinoma"}, {"text": "Liver cancer", "relevance": 0.213416, "dbpedia_resource": "http://dbpedia.org/resource/Liver_cancer"}, {"text": "Gallbladder", "relevance": 0.212541, "dbpedia_resource": "http://dbpedia.org/resource/Gallbladder"}], "categories": [{"score": 0.950979, "label": "/health and fitness/disease"}, {"score": 0.900608, "label": "/health and fitness/disease/cancer"}, {"score": 0.878033, "label": "/health and fitness/therapy"}], "relations": [{"type": "hasAttribute", "sentence": "HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis.", "score": 0.891192, "arguments": [{"text": "patients", "location": [141, 149], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic liver diseases", "location": [155, 177], "entities": [{"type": "HealthCondition", "text": "chronic liver diseases"}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.482026, "arguments": [{"text": "companies", "location": [3837, 3846], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Teva pharmaceutical Industries Ltd.", "location": [3746, 3781], "entities": [{"type": "Organization", "text": "Teva pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.431826, "arguments": [{"text": "companies", "location": [3837, 3846], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Pfizer Inc.", "location": [3783, 3794], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.790481, "arguments": [{"text": "companies", "location": [3837, 3846], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda Pharmaceutical Co. Ltd.", "location": [3800, 3830], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis.", "score": 0.872374, "arguments": [{"text": "patients", "location": [141, 149], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cirrhosis", "location": [182, 191], "entities": [{"type": "HealthCondition", "text": "cirrhosis"}]}]}, {"type": "agentOf", "sentence": "The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation.", "score": 0.465097, "arguments": [{"text": "HCC", "location": [216, 219], "entities": [{"type": "Organization", "text": "HCC"}]}, {"text": "investigation", "location": [285, 298], "entities": [{"type": "EventLegal", "text": "investigation"}]}]}, {"type": "populationOf", "sentence": "The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2015.", "score": 0.352493, "arguments": [{"text": "39,230", "location": [1135, 1141], "entities": [{"type": "Cardinal", "text": "39,230"}]}, {"text": "U.S.", "location": [1112, 1116], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "score": 0.670053, "arguments": [{"text": "APEJ", "location": [2808, 2812], "entities": [{"type": "GeopoliticalEntity", "text": "APEJ"}]}, {"text": "Japan", "location": [2814, 2819], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1370 Bayer AG is one of the leading provider of hepatocellular carcinoma (HCC) treatment drugs.", "score": 0.552825, "arguments": [{"text": "Report Sample@", "location": [3355, 3369], "entities": [{"type": "Person", "text": "Report Sample@"}]}, {"text": "Request", "location": [3347, 3354], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "partOfMany", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.811736, "arguments": [{"text": "Some", "location": [3524, 3528], "entities": [{"type": "Cardinal", "text": "Some"}]}, {"text": "players", "location": [3540, 3547], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.423466, "arguments": [{"text": "companies", "location": [3837, 3846], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Celgen Corporation", "location": [3714, 3732], "entities": [{"type": "Organization", "text": "Celgen Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.505414, "arguments": [{"text": "companies", "location": [3837, 3846], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Amgen Inc.", "location": [3734, 3744], "entities": [{"type": "Organization", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Hepatocellular carcinoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.825267, "count": 1}, {"text": "hepatocellular carcinoma treatment market", "sentiment": {"score": -0.703064, "label": "negative"}, "relevance": 0.724518, "count": 2}, {"text": "hepatitis C virus", "sentiment": {"score": -0.837245, "label": "negative"}, "relevance": 0.662417, "count": 3}, {"text": "uncommon hepatocellular carcinoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.644874, "count": 1}, {"text": "technological advancements", "sentiment": {"score": 0.749622, "label": "positive"}, "relevance": 0.630941, "count": 1}, {"text": "Hepatitis B virus", "sentiment": {"score": -0.892406, "label": "negative"}, "relevance": 0.590151, "count": 2}, {"text": "effective treatment procedures", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.585884, "count": 1}, {"text": "cells of origin of HCC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58578, "count": 1}, {"text": "early detection of hepatocellular carcinoma", "sentiment": {"score": 0.264228, "mixed": "1", "label": "positive"}, "relevance": 0.58326, "count": 1}, {"text": "increasing investment of pharmaceutical companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578747, "count": 1}, {"text": "incidence rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.574166, "count": 1}, {"text": "hepatic stem cells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57134, "count": 1}, {"text": "Monoclonal antibodies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.56628, "count": 1}, {"text": "hepatocellular carcinoma", "sentiment": {"score": -0.895473, "label": "negative"}, "relevance": 0.564327, "count": 1}, {"text": "risk factors", "sentiment": {"score": -0.895473, "label": "negative"}, "relevance": 0.561828, "count": 1}, {"text": "North America", "sentiment": {"score": -0.672214, "label": "negative"}, "relevance": 0.560803, "count": 2}, {"text": "infection", "sentiment": {"score": -0.893432, "label": "negative"}, "relevance": 0.555969, "count": 3}, {"text": "Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554863, "count": 1}, {"text": "incidences of hepatocellular carcinoma", "sentiment": {"score": -0.703064, "label": "negative"}, "relevance": 0.554412, "count": 1}, {"text": "Western Europe", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.553433, "count": 1}, {"text": "HCC", "sentiment": {"score": -0.782684, "label": "negative"}, "relevance": 0.551639, "count": 9}, {"text": "multinational companies", "sentiment": {"score": 0.412252, "mixed": "1", "label": "positive"}, "relevance": 0.55124, "count": 1}, {"text": "advancement", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.543589, "count": 1}, {"text": "Middle East", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.536801, "count": 1}, {"text": "priority areas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536053, "count": 1}, {"text": "Latin America", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.535686, "count": 1}, {"text": "Eastern Europe", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.534536, "count": 1}, {"text": "Chemotherapy", "sentiment": {"score": -0.674131, "label": "negative"}, "relevance": 0.533958, "count": 1}, {"text": "chemotherapy", "sentiment": {"score": -0.824227, "label": "negative"}, "relevance": 0.533958, "count": 1}, {"text": "HBV", "sentiment": {"score": -0.892406, "label": "negative"}, "relevance": 0.53222, "count": 2}, {"text": "technologies", "sentiment": {"score": -0.674131, "label": "negative"}, "relevance": 0.530384, "count": 1}, {"text": "technology", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.530384, "count": 1}, {"text": "major malignancy of the liver", "sentiment": {"score": -0.806673, "label": "negative"}, "relevance": 0.530236, "count": 1}, {"text": "metabolic syndrome", "sentiment": {"score": -0.895473, "label": "negative"}, "relevance": 0.529496, "count": 1}, {"text": "HCV", "sentiment": {"score": -0.892406, "label": "negative"}, "relevance": 0.528943, "count": 2}, {"text": "cost", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.528588, "count": 1}, {"text": "infections", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.528073, "count": 1}, {"text": "high cost of treatment", "sentiment": {"score": -0.824227, "label": "negative"}, "relevance": 0.526457, "count": 1}, {"text": "factors", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.526414, "count": 1}, {"text": "pharmaceutical Industries Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525585, "count": 1}, {"text": "investment", "sentiment": {"score": -0.342438, "label": "negative"}, "relevance": 0.524467, "count": 1}, {"text": "advanced stage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524286, "count": 1}, {"text": "Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52197, "count": 1}, {"text": "Teva", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521371, "count": 1}, {"text": "market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520381, "count": 1}, {"text": "application", "sentiment": {"score": -0.674131, "label": "negative"}, "relevance": 0.519472, "count": 1}, {"text": "biliary cirrhosis", "sentiment": {"score": -0.895473, "label": "negative"}, "relevance": 0.519444, "count": 1}, {"text": "Brachytherapy", "sentiment": {"score": -0.674131, "label": "negative"}, "relevance": 0.519382, "count": 1}, {"text": "Celgen Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519246, "count": 1}, {"text": "liver disease", "sentiment": {"score": 0.749622, "label": "positive"}, "relevance": 0.518227, "count": 1}]}, "extracted_metadata": {"sha1": "e268e129e369bf5cdfc57907450c990a0bb28d3f", "filename": "1542830131751.zip-d25afdbf1a28fa2db00f3fe77bdbc0e0.xml", "file_type": "json"}, "external_links": ["http://www.futuremarketinsights.com/reports/hepatocellular-carcinoma-hcc-treatment-market", "http://www.futuremarketinsights.com/reports/sample/rep-gb-1370"], "title": "Hepatocellular Carcinoma HCC Treatment Growth Factors and Industry Analysis 2016-2026", "forum_title": "Research Insights | Find Market Research - Part 29"}, {"id": "BJsE-vmMQd0D2qwalyAcqTbBX-I_h9NCI1HDQ5GP4BtpGtWLOXWujOfZT85NCJZP", "result_metadata": {"score": 35.842537}, "author": "wn.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.911168, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.701193, "label": "/law, govt and politics/government"}], "relations": [], "keywords": [{"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995872, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.855862, "count": 1}]}, "crawl_date": "2018-11-22T08:12:09Z", "url": "https://article.wn.com/view/2018/11/22/Form_83_TAKEDA_PHARMACEUTICAL_CO_LTD_AMENDMENT/", "host": "article.wn.com", "text": "LONDON--(BUSINESS WIRE )-- FORM 8.3 Amendment to Purchases & Sales PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the ' Code ') 1. KEY INFORMATION (a) Full name of", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.75, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.75, "type": "Quantity"}], "sentiment": {"document": {"score": -0.575545, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}], "concepts": [{"text": "Childbirth", "relevance": 0.85667, "dbpedia_resource": "http://dbpedia.org/resource/Childbirth"}, {"text": "Jay-Z", "relevance": 0.828571, "dbpedia_resource": "http://dbpedia.org/resource/Jay-Z"}, {"text": "Marketing", "relevance": 0.787405, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Cryptography", "relevance": 0.736475, "dbpedia_resource": "http://dbpedia.org/resource/Cryptography"}, {"text": "Cipher", "relevance": 0.722822, "dbpedia_resource": "http://dbpedia.org/resource/Cipher"}], "categories": [{"score": 0.838389, "label": "/finance/financial news"}, {"score": 0.761106, "label": "/business and industrial"}, {"score": 0.75654, "label": "/real estate/buying and selling homes"}], "relations": [], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.882259, "count": 1}, {"text": "PERSON", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.812137, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.776417, "count": 1}, {"text": "FORM", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.738895, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.695646, "count": 1}, {"text": "LONDON", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.692232, "count": 1}, {"text": "Amendment", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.636981, "count": 1}, {"text": "Purchases", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.597386, "count": 1}, {"text": "Code", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.591566, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.586814, "count": 1}, {"text": "Sales", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.576267, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.505069, "count": 1}, {"text": "BUSINESS WIRE", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.487624, "count": 1}, {"text": "Full name", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470142, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.431247, "count": 1}]}, "extracted_metadata": {"sha1": "7199b03664f987b1a816aac98f19e12636b1875f", "filename": "1542874329238.zip-b19d8dede0d999706691a3d91db3ee0f.xml", "file_type": "json"}, "title": "Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD AMENDMENT", "forum_title": "WN.com - Business News"}, {"id": "yeO0__phgwKmck8plT59Ads1uYKZCSvePoDfQq2NYd5w6nefuLxm3kzS_KpDQ4nR", "result_metadata": {"score": 35.727856}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London Stock Exchange", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Stock market", "relevance": 0.928193, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "London Stock Exchange", "relevance": 0.81081, "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}, {"text": "Stock exchange", "relevance": 0.767321, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "London", "relevance": 0.5355, "dbpedia_resource": "http://dbpedia.org/resource/London"}, {"text": "Stock", "relevance": 0.518143, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}], "categories": [{"score": 0.861029, "label": "/finance/investing"}, {"score": 0.861029, "label": "/finance/investing/beginning investing"}, {"score": 0.832083, "label": "/finance/investing/day trading"}], "relations": [], "keywords": [{"text": "London Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999792, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.737769, "count": 1}, {"text": "HBK Investments LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.711641, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370926, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.046997, "count": 1}]}, "crawl_date": "2018-11-22T14:32:39Z", "url": "https://www.marketscreener.com/LONDON-STOCK-EXCHANGE-4005918/news/London-Stock-Exchange-HBK-Investments-LP-Form-8-3-Takeda-Pharmaceutical-Co-Ltd-27649473/", "host": "marketscreener.com", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-22T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.615292, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.555288, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.533409, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jonathan Brown", "relevance": 0.509256, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501351, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.49167, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.473279, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.473279, "type": "Quantity"}], "sentiment": {"document": {"score": 0.570084, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "for each offeror/offeree Takeda Pharmaceutical Co Ltd (d)", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "with an offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "connect", "tense": "past"}, "text": "connected", "normalized": "connect"}}, {"subject": {"text": "a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}, {"text": "exempt fund manager"}, {"text": "separate form"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}, {"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "state the latest practicable date prior to the disclosure 21 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "latest practicable date"}, {"text": "disclosure"}, {"text": "addition"}, {"text": "state"}]}, "sentence": " For an opening position disclosure, state the latest practicable date prior to the disclosure 21 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d YES : Shire Plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " 1.078 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "1.078 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " 1.078 All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Exercising/", "keywords": [{"text": "Exercising/"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "e.g. call option", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "exercised", "normalized": "exercise"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "the Code", "keywords": [{"text": "Code"}]}, "sentence": " Date of disclosure: 22 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "made to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.963351, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.525439, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.506563, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.500265, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Futures contract", "relevance": 0.473383, "dbpedia_resource": "http://dbpedia.org/resource/Futures_contract"}, {"text": "Contract", "relevance": 0.454204, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.424716, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.414623, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.408951, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Security", "relevance": 0.384711, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Stock", "relevance": 0.375584, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Unit type", "relevance": 0.372536, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.364666, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Security", "relevance": 0.349327, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.3477, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.339448, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Derivative", "relevance": 0.339372, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Moneyness", "relevance": 0.338791, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.940229, "label": "/real estate/buying and selling homes"}, {"score": 0.870315, "label": "/finance/financial news"}, {"score": 0.797611, "label": "/finance/investing/funds"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [311, 316], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [289, 292], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: Ordinary (ISIN: JP3463 4) Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 100 0.000 0 0.000 (2) Cash-settled derivatives: 8,454,400 1.078 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:  TOTAL: 100 0.000 8,454,400 1.078 All interests and all short positions should be disclosed.", "score": 0.531913, "arguments": [{"text": "Number % Number %", "location": [1682, 1699], "entities": [{"type": "Organization", "text": "Number % Number %", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Interests Short", "location": [1656, 1671], "entities": [{"type": "Organization", "text": "Interests Short", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit Ordinary Total Return Swap Increasing a short position 400,000 USD 38.3152 (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.787391, "arguments": [{"text": "i", "location": [3270, 3271], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3273, 3280], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3870, 3875], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3880, 3884], "entities": [{"type": "Organization", "text": "Price per unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4244, 4250], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4261, 4268], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 22 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [5151, 5157], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5165, 5169], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5232, 5256], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5224, 5229], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5511, 5535], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5503, 5508], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5567, 5572], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5586, 5613], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.797526, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.680735, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.65994, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.645739, "count": 3}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.639211, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.607144, "count": 1}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589674, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.589434, "count": 2}, {"text": "short positions", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.586392, "count": 3}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.56582, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563322, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554766, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553186, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.548796, "count": 1}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.544262, "count": 1}, {"text": "options", "sentiment": {"score": 0.688082, "label": "positive"}, "relevance": 0.542376, "count": 4}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.542172, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.542172, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.541161, "count": 2}, {"text": "PERSON", "sentiment": {"score": 0.569891, "label": "positive"}, "relevance": 0.541158, "count": 2}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.539213, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537976, "count": 1}, {"text": "unit", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.536745, "count": 4}, {"text": "subscription", "sentiment": {"score": 0.684266, "label": "positive"}, "relevance": 0.536407, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.536299, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.535779, "count": 4}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.535583, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.534939, "count": 2}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534539, "count": 1}, {"text": "relation", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.533131, "count": 3}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.532065, "count": 1}, {"text": "Jonathan Brown Telephone number", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.531611, "count": 1}, {"text": "telephone number", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.530012, "count": 1}, {"text": "November", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.529667, "count": 2}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528641, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.528627, "count": 6}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528295, "count": 2}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.528152, "count": 1}, {"text": "contact information", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.528046, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.527952, "count": 1}, {"text": "Code", "sentiment": {"score": -0.536992, "mixed": "1", "label": "negative"}, "relevance": 0.527611, "count": 3}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527575, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.527575, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.525073, "count": 3}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.525004, "count": 3}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524903, "count": 1}, {"text": "Contact name", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.524788, "count": 1}, {"text": "funds", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.524442, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524223, "count": 2}, {"text": "Purchases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524108, "count": 1}]}, "extracted_metadata": {"sha1": "17bdbbc6985ffc5203200688980234355e033886", "filename": "1542897159073.zip-fdeea50353a6649a22d8b96f6f881d2d.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk/"], "title": "London Stock Exchange : HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "lP9mrRNYH-ddSNL1goPk1njRSeNR7x9fcfgzh8Bgs0GV-3Z3Uu2LtSyoxFe2XJ94", "result_metadata": {"score": 35.26687}, "author": "Market Research Future", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}], "sentiment": {"document": {"score": 0.563317, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Wall Street Crash of 1929", "relevance": 0.919945, "dbpedia_resource": "http://dbpedia.org/resource/Wall_Street_Crash_of_1929"}], "categories": [{"score": 0.923081, "label": "/health and fitness"}, {"score": 0.693376, "label": "/health and fitness/drugs"}], "relations": [{"type": "locatedAt", "sentence": "Gastrointestinal Drugs Market Trend in America 2018 to 2023 | Perceive Accruals USD 59.3 Bn | Healthy Evolving Growth Rate | MarketResearchFuture.com", "score": 0.688579, "arguments": [{"text": "Gastrointestinal Drugs Market Trend", "location": [0, 35], "entities": [{"type": "Organization", "text": "Gastrointestinal Drugs Market Trend"}]}, {"text": "America", "location": [39, 46], "entities": [{"type": "GeopoliticalEntity", "text": "America", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "Gastrointestinal Drugs Market Trend", "sentiment": {"score": 0.563317, "label": "positive"}, "relevance": 0.978512, "count": 1}, {"text": "Perceive Accruals USD", "sentiment": {"score": 0.563317, "label": "positive"}, "relevance": 0.756753, "count": 1}, {"text": "America", "sentiment": {"score": 0.563317, "label": "positive"}, "relevance": 0.714046, "count": 1}, {"text": "Healthy Evolving Growth Rate", "sentiment": {"score": 0.563317, "label": "positive"}, "relevance": 0.62113, "count": 1}, {"text": "com", "sentiment": {"score": 0.563317, "label": "positive"}, "relevance": 0.560129, "count": 1}, {"text": "Bn", "sentiment": {"score": 0.563317, "label": "positive"}, "relevance": 0.239861, "count": 1}, {"text": "MarketResearchFuture", "sentiment": {"score": 0.563317, "label": "positive"}, "relevance": 0.16497, "count": 1}]}, "crawl_date": "2018-11-22T09:19:55Z", "url": "https://www.openpr.com/news/1391480/Gastrointestinal-Drugs-Market-Trend-in-America-2018-to-2023-Perceive-Accruals-USD-59-3-Bn-Healthy-Evolving-Growth-Rate-MarketResearchFuture-com.html", "host": "openpr.com", "text": "(US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-22T09:08:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Americas Gastrointestinal Drug", "relevance": 0.921882, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.749291, "label": "negative"}, "text": "ulcerative disease", "relevance": 0.623252, "type": "HealthCondition"}, {"count": 3, "sentiment": {"score": 0.553221, "label": "positive"}, "text": "US", "relevance": 0.616372, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.312818, "label": "negative"}, "text": "North America", "relevance": 0.586078, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.579524, "label": "negative"}, "text": "intestinal diseases", "relevance": 0.540869, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.53644, "type": "Organization", "disambiguation": {"subtype": ["BuildingFunction"], "name": "School", "dbpedia_resource": "http://dbpedia.org/resource/School"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Janssen Biotech Inc.", "relevance": 0.490929, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.401971, "label": "negative"}, "text": "Valent Pharmaceuticals", "relevance": 0.462086, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.451686, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.637699, "label": "negative"}, "text": "bowel syndrome", "relevance": 0.449184, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.429813, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.426603, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.423492, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Germany", "dbpedia_resource": "http://dbpedia.org/resource/Germany"}}, {"count": 1, "sentiment": {"score": -0.425904, "label": "negative"}, "text": "Valeant Pharmaceuticals", "relevance": 0.415701, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0.344693, "label": "positive"}, "text": "South America", "relevance": 0.384948, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Antiemetic", "relevance": 0.381411, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan Plc", "relevance": 0.367494, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.36733, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.363493, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.357153, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 1, "sentiment": {"score": -0.223252, "label": "negative"}, "text": "Bayer AG", "relevance": 0.349076, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.346603, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.339126, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc.", "relevance": 0.333848, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co., Ltd.", "relevance": 0.324819, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.315211, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.763788, "label": "negative"}, "text": "pancolitis", "relevance": 0.309763, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.309763, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.801536, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "pharmacological and non-pharmacological treatment", "keywords": [{"text": "non-pharmacological treatment"}]}, "sentence": "Press release from: Market Research Future Gastrointestinal Drugs Market Americas Gastrointestinal Drugs Market - HighlightsGastrointestinal (GI) drug market involves pharmacological and non-pharmacological treatment.", "object": {"text": "Market Research Future Gastrointestinal Drugs Market Americas Gastrointestinal Drugs Market - HighlightsGastrointestinal (GI) drug market", "keywords": [{"text": "Americas Gastrointestinal Drugs"}, {"text": "Gastrointestinal Drugs Market"}, {"text": "Future Gastrointestinal Drugs"}]}, "action": {"verb": {"text": "involve", "tense": "present"}, "text": "involves", "normalized": "involve"}}, {"subject": {"text": "constipation, diverticular diseases, colon polyps, irritable bowel syndrome", "keywords": [{"text": "irritable bowel syndrome"}, {"text": "colon polyps"}, {"text": "constipation"}, {"text": "diverticular diseases"}], "entities": [{"type": "HealthCondition", "text": "bowel syndrome"}]}, "sentence": " Different types of gastrointestinal disorder includes constipation, diverticular diseases, colon polyps, irritable bowel syndrome, and many more.", "object": {"text": "Different types of gastrointestinal disorder", "keywords": [{"text": "gastrointestinal disorder"}, {"text": "Different types"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Many of the GI diseases", "keywords": [{"text": "GI diseases"}]}, "sentence": " Many of the GI diseases can be prevented and minimized by maintaining a healthy lifestyle and balanced diet.The factors like increasing prevalence of increasing of various different gastrointestinal disease, increasing elderly population, technological advances are responsible for driving gastrointestinal market.", "object": {"text": "a healthy lifestyle", "keywords": [{"text": "healthy lifestyle"}]}, "action": {"verb": {"text": "maintain", "tense": "present"}, "text": "maintaining", "normalized": "maintain"}}, {"subject": {"text": "technological advances", "keywords": [{"text": "technological advances"}]}, "sentence": " Many of the GI diseases can be prevented and minimized by maintaining a healthy lifestyle and balanced diet.The factors like increasing prevalence of increasing of various different gastrointestinal disease, increasing elderly population, technological advances are responsible for driving gastrointestinal market.", "object": {"text": "responsible for driving gastrointestinal market", "keywords": [{"text": "gastrointestinal market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "technological advances", "keywords": [{"text": "technological advances"}]}, "sentence": " Many of the GI diseases can be prevented and minimized by maintaining a healthy lifestyle and balanced diet.The factors like increasing prevalence of increasing of various different gastrointestinal disease, increasing elderly population, technological advances are responsible for driving gastrointestinal market.", "object": {"text": "gastrointestinal market", "keywords": [{"text": "gastrointestinal market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "driving", "normalized": "drive"}}, {"subject": {"text": "the drug category the market", "keywords": [{"text": "drug category"}, {"text": "market"}]}, "sentence": " On the basis of the drug category the market is segmented into Acid Neutralizers, Laxatives & Antidiarrheal, Anti-inflammatory, Antiemetic and others.", "object": {"text": "into Acid Neutralizers, Laxatives & Antidiarrheal, Anti-inflammatory, Antiemetic and others", "keywords": [{"text": "Acid Neutralizers"}, {"text": "Antiemetic"}, {"text": "Anti-inflammatory"}, {"text": "Laxatives"}], "entities": [{"type": "Person", "text": "Antiemetic"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "Further the Acid Neutralizers", "keywords": [{"text": "Acid Neutralizers"}]}, "sentence": " Further the Acid Neutralizers are sub-segmented into Antacid, H2 antagonists, Proton Pump Inhibitors and others.", "object": {"text": "sub-segmented into Antacid, H2 antagonists, Proton Pump Inhibitors and others", "keywords": [{"text": "Proton Pump Inhibitors"}, {"text": "H2 antagonists"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "oral, parental and rectal"}, "sentence": " On the basis of route of administration the segments includes oral, parental and rectal.", "object": {"text": "On the basis of route of administration the segments", "keywords": [{"text": "segments"}, {"text": "basis"}, {"text": "route"}, {"text": "administration"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "On the basis of disease type, market", "keywords": [{"text": "basis"}, {"text": "disease type"}, {"text": "market"}]}, "sentence": " On the basis of disease type, market is segmented into gastro-esophageal reflux diseases, inflammatory bowel diseases and others.", "object": {"text": "segmented into gastro-esophageal reflux diseases, inflammatory bowel diseases and others", "keywords": [{"text": "gastro-esophageal reflux diseases"}, {"text": "inflammatory bowel diseases"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "market", "keywords": [{"text": "market"}]}, "sentence": " On the basis of disease type, market is segmented into gastro-esophageal reflux diseases, inflammatory bowel diseases and others.", "object": {"text": "into gastro-esophageal reflux diseases, inflammatory bowel diseases and others", "keywords": [{"text": "gastro-esophageal reflux diseases"}, {"text": "inflammatory bowel diseases"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The inflammatory diseases", "keywords": [{"text": "inflammatory diseases"}]}, "sentence": " The inflammatory diseases are further segmented into two types Crohn\u2019s diseases and ulcerative disease.", "object": {"text": "further segmented into two types Crohn\u2019s diseases and ulcerative disease", "keywords": [{"text": "types Crohn"}, {"text": "ulcerative disease"}, {"text": "diseases"}], "entities": [{"type": "HealthCondition", "text": "ulcerative disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The Ulcerative diseases", "keywords": [{"text": "Ulcerative diseases"}], "entities": [{"type": "HealthCondition", "text": "ulcerative disease"}]}, "sentence": " The Ulcerative diseases are further sub segmented into ulcerative protitis, proctosigmoiditis, left sided colitis, pancolitis and acute severe ulcerartive colitis.", "object": {"text": "further sub", "keywords": [{"text": "sub"}], "entities": [{"type": "HealthCondition", "text": "ulcerative disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "further sub", "keywords": [{"text": "sub"}], "entities": [{"type": "HealthCondition", "text": "ulcerative disease"}]}, "sentence": " The Ulcerative diseases are further sub segmented into ulcerative protitis, proctosigmoiditis, left sided colitis, pancolitis and acute severe ulcerartive colitis.", "object": {"text": "into ulcerative protitis", "keywords": [{"text": "ulcerative protitis"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "segmented", "normalized": "segment"}}, {"subject": {"text": "hospital pharmacies, retail pharmacies and others.Americas Gastrointestinal Drugs Market - Regional AnalysisOn regional basis America gastrointestinal drug market is segmented into two main region- North America, and South America", "keywords": [{"text": "others.Americas Gastrointestinal Drugs"}, {"text": "gastrointestinal drug market"}, {"text": "hospital pharmacies"}, {"text": "retail pharmacies"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "South America", "disambiguation": {"subtype": ["Region"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}]}, "sentence": " The end user segment includes hospital pharmacies, retail pharmacies and others.Americas Gastrointestinal Drugs Market - Regional AnalysisOn regional basis America gastrointestinal drug market is segmented into two main region- North America, and South America.", "object": {"text": "The end user segment", "keywords": [{"text": "end user segment"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America has the highest market for the gastrointestinal drug market.", "object": {"text": "the highest market for the gastrointestinal drug market", "keywords": [{"text": "gastrointestinal drug market"}, {"text": "highest market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Increasing Geriatric Population", "keywords": [{"text": "Geriatric Population"}]}, "sentence": " Increasing Geriatric Population is the major driving factor for the market of GI drugs in North America.", "object": {"text": "the major driving factor for the market of GI drugs in North America", "keywords": [{"text": "major driving factor"}, {"text": "GI drugs"}, {"text": "North America"}, {"text": "market"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Region"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the major cause of the gastrointestinal diseases", "keywords": [{"text": "gastrointestinal diseases"}, {"text": "major cause"}]}, "sentence": " While the major cause of the gastrointestinal diseases is stress full life and eating habit.Browse Complete 50 Pages Premium Research Report Enabled with Respective Tables and Figures at www.marketresearchfuture.com/reports/americas-gastrointes...", "object": {"text": "stress full life", "keywords": [{"text": "stress full life"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Gastroenterology", "relevance": 0.98686, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Ulcerative colitis", "relevance": 0.803785, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Pharmacology", "relevance": 0.700438, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Inflammation", "relevance": 0.613826, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Irritable bowel syndrome", "relevance": 0.606202, "dbpedia_resource": "http://dbpedia.org/resource/Irritable_bowel_syndrome"}, {"text": "North America", "relevance": 0.56455, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Diverticulitis", "relevance": 0.561354, "dbpedia_resource": "http://dbpedia.org/resource/Diverticulitis"}, {"text": "Constipation", "relevance": 0.551147, "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}, {"text": "Digestive disease", "relevance": 0.513806, "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}, {"text": "Pharmaceutical drug", "relevance": 0.499413, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Inflammatory bowel disease", "relevance": 0.492796, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Digestive diseases", "relevance": 0.4751, "dbpedia_resource": "http://dbpedia.org/resource/Digestive_diseases"}, {"text": "Americas", "relevance": 0.470643, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Boehringer Ingelheim", "relevance": 0.454957, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Crohn's disease", "relevance": 0.432979, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "Medicine", "relevance": 0.426621, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Flatulence", "relevance": 0.424623, "dbpedia_resource": "http://dbpedia.org/resource/Flatulence"}, {"text": "South America", "relevance": 0.404867, "dbpedia_resource": "http://dbpedia.org/resource/South_America"}, {"text": "Pharmacy", "relevance": 0.396687, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Intestine", "relevance": 0.382687, "dbpedia_resource": "http://dbpedia.org/resource/Intestine"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.380883, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Latin America", "relevance": 0.372984, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Colonoscopy", "relevance": 0.370309, "dbpedia_resource": "http://dbpedia.org/resource/Colonoscopy"}, {"text": "Functional colonic disease", "relevance": 0.355509, "dbpedia_resource": "http://dbpedia.org/resource/Functional_colonic_disease"}, {"text": "United States", "relevance": 0.354547, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Ingelheim am Rhein", "relevance": 0.353031, "dbpedia_resource": "http://dbpedia.org/resource/Ingelheim_am_Rhein"}, {"text": "Drug", "relevance": 0.351983, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Immune system", "relevance": 0.351671, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Caribbean", "relevance": 0.3513, "dbpedia_resource": "http://dbpedia.org/resource/Caribbean"}, {"text": "Biotechnology companies", "relevance": 0.348096, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Multinational companies", "relevance": 0.344193, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Indigenous peoples of the Americas", "relevance": 0.343159, "dbpedia_resource": "http://dbpedia.org/resource/Indigenous_peoples_of_the_Americas"}, {"text": "Americas", "relevance": 0.340972, "dbpedia_resource": "http://dbpedia.org/resource/Americas_(terminology)"}, {"text": "Dietary fiber", "relevance": 0.338695, "dbpedia_resource": "http://dbpedia.org/resource/Dietary_fiber"}, {"text": "Colitis", "relevance": 0.337865, "dbpedia_resource": "http://dbpedia.org/resource/Colitis"}, {"text": "Large intestine", "relevance": 0.335635, "dbpedia_resource": "http://dbpedia.org/resource/Large_intestine"}, {"text": "Gastroesophageal reflux disease", "relevance": 0.329983, "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}, {"text": "Colon", "relevance": 0.327523, "dbpedia_resource": "http://dbpedia.org/resource/Colon_(anatomy)"}, {"text": "Codeine", "relevance": 0.326809, "dbpedia_resource": "http://dbpedia.org/resource/Codeine"}, {"text": "Anti-inflammatory", "relevance": 0.325252, "dbpedia_resource": "http://dbpedia.org/resource/Anti-inflammatory"}, {"text": "Disease", "relevance": 0.315033, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Abdominal pain", "relevance": 0.313145, "dbpedia_resource": "http://dbpedia.org/resource/Abdominal_pain"}, {"text": "Indigenous languages of the Americas", "relevance": 0.305795, "dbpedia_resource": "http://dbpedia.org/resource/Indigenous_languages_of_the_Americas"}, {"text": "Drugs", "relevance": 0.304784, "dbpedia_resource": "http://dbpedia.org/resource/Drugs"}, {"text": "Digestive system", "relevance": 0.298091, "dbpedia_resource": "http://dbpedia.org/resource/Digestive_system"}, {"text": "Portuguese language", "relevance": 0.292815, "dbpedia_resource": "http://dbpedia.org/resource/Portuguese_language"}, {"text": "Infection", "relevance": 0.288808, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Pharmaceutical industry", "relevance": 0.285385, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Central America", "relevance": 0.275069, "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}, {"text": "Laxative", "relevance": 0.274885, "dbpedia_resource": "http://dbpedia.org/resource/Laxative"}], "categories": [{"score": 0.978216, "label": "/health and fitness/disease"}, {"score": 0.90664, "label": "/health and fitness/disease/ibs and crohn's disease"}, {"score": 0.880073, "label": "/health and fitness/disease/gerd and acid reflux"}], "relations": [{"type": "employedBy", "sentence": "Request Sample Report @ www.marketresearchfuture.com/sample_request/583 Americas Gastrointestinal Drugs Market - PlayersThe players in global and local gastrointestinal drug market are AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc.", "score": 0.463371, "arguments": [{"text": "players", "location": [929, 936], "entities": [{"type": "Person", "text": "players"}]}, {"text": "Americas Gastrointestinal Drugs Market", "location": [877, 915], "entities": [{"type": "Organization", "text": "Americas Gastrointestinal Drugs Market - Regional AnalysisOn"}]}]}, {"type": "employedBy", "sentence": "Request Sample Report @ www.marketresearchfuture.com/sample_request/583 Americas Gastrointestinal Drugs Market - PlayersThe players in global and local gastrointestinal drug market are AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc.", "score": 0.979919, "arguments": [{"text": "AstraZeneca", "location": [1008, 1019], "entities": [{"type": "Person", "text": "AstraZeneca"}]}, {"text": "UK", "location": [1021, 1023], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "locatedAt", "sentence": "Request Sample Report @ www.marketresearchfuture.com/sample_request/583 Americas Gastrointestinal Drugs Market - PlayersThe players in global and local gastrointestinal drug market are AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc.", "score": 0.413344, "arguments": [{"text": "Valeant", "location": [1026, 1033], "entities": [{"type": "Person", "text": "Valeant"}]}, {"text": "US", "location": [1035, 1037], "entities": [{"type": "GeopoliticalEntity", "text": "America", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Request Sample Report @ www.marketresearchfuture.com/sample_request/583 Americas Gastrointestinal Drugs Market - PlayersThe players in global and local gastrointestinal drug market are AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc.", "score": 0.733991, "arguments": [{"text": "Sanofi", "location": [1233, 1239], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}, {"text": "France", "location": [1241, 1247], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "On the basis of the drug category the market is segmented into Acid Neutralizers, Laxatives & Antidiarrheal, Anti-inflammatory, Antiemetic and others.", "score": 0.491058, "arguments": [{"text": "Anti", "location": [1678, 1682], "entities": [{"type": "Person", "text": "Anti"}]}, {"text": "others", "location": [1712, 1718], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "hasAttribute", "sentence": "The inflammatory diseases are further segmented into two types Crohn's diseases and ulcerative disease.", "score": 0.875353, "arguments": [{"text": "Crohn", "location": [2115, 2120], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "diseases", "location": [2123, 2131], "entities": [{"type": "HealthCondition", "text": "inflammatory diseases"}]}]}, {"type": "locatedAt", "sentence": "Increasing Geriatric Population is the major driving factor for the market of GI drugs in North America.", "score": 0.633627, "arguments": [{"text": "drugs", "location": [2738, 2743], "entities": [{"type": "Substance", "text": "Antacid"}]}, {"text": "North America", "location": [2747, 2760], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "diverticular diseases", "sentiment": {"score": -0.960088, "label": "negative"}, "relevance": 0.734711, "count": 1}, {"text": "Different types of gastrointestinal disorder", "sentiment": {"score": -0.960088, "label": "negative"}, "relevance": 0.613192, "count": 1}, {"text": "basis of drug category", "sentiment": {"score": -0.849561, "label": "negative"}, "relevance": 0.609393, "count": 1}, {"text": "GI diseases", "sentiment": {"score": -0.429369, "label": "negative"}, "relevance": 0.605329, "count": 1}, {"text": "US", "sentiment": {"score": -0.849561, "label": "negative"}, "relevance": 0.596621, "count": 8}, {"text": "various different gastrointestinal disease", "sentiment": {"score": -0.429369, "label": "negative"}, "relevance": 0.59191, "count": 1}, {"text": "drug market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589214, "count": 1}, {"text": "segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587009, "count": 1}, {"text": "elderly population", "sentiment": {"score": -0.429369, "label": "negative"}, "relevance": 0.580473, "count": 1}, {"text": "healthy lifestyle", "sentiment": {"score": -0.429369, "label": "negative"}, "relevance": 0.577062, "count": 1}, {"text": "Americas Gastrointestinal Drugs Market", "sentiment": {"score": -0.853083, "label": "negative"}, "relevance": 0.574939, "count": 3}, {"text": "North America", "sentiment": {"score": -0.607916, "label": "negative"}, "relevance": 0.561411, "count": 3}, {"text": "Press release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560599, "count": 1}, {"text": "major driving factor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555808, "count": 1}, {"text": "gastrointestinal market", "sentiment": {"score": -0.669265, "label": "negative"}, "relevance": 0.550333, "count": 1}, {"text": "irritable bowel syndrome", "sentiment": {"score": -0.960088, "label": "negative"}, "relevance": 0.547375, "count": 1}, {"text": "local gastrointestinal drug market", "sentiment": {"score": -0.856525, "label": "negative"}, "relevance": 0.546054, "count": 1}, {"text": "factors", "sentiment": {"score": -0.429369, "label": "negative"}, "relevance": 0.54216, "count": 1}, {"text": "GI", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541977, "count": 1}, {"text": "Abbott Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541462, "count": 1}, {"text": "technological advances", "sentiment": {"score": -0.429369, "label": "negative"}, "relevance": 0.540641, "count": 1}, {"text": "Valeant Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540174, "count": 1}, {"text": "end user segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540007, "count": 1}, {"text": "inflammatory diseases", "sentiment": {"score": -0.805264, "label": "negative"}, "relevance": 0.537509, "count": 1}, {"text": "Request Sample Report", "sentiment": {"score": -0.856525, "label": "negative"}, "relevance": 0.535883, "count": 1}, {"text": "market", "sentiment": {"score": -0.9144, "label": "negative"}, "relevance": 0.535133, "count": 2}, {"text": "basis of the drug category", "sentiment": {"score": -0.86354, "label": "negative"}, "relevance": 0.535061, "count": 1}, {"text": "regional basis America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532319, "count": 1}, {"text": "Americas", "sentiment": {"score": -0.849561, "label": "negative"}, "relevance": 0.531718, "count": 1}, {"text": "Regional AnalysisOn", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531352, "count": 1}, {"text": "intestinal diseases", "sentiment": {"score": -0.856525, "label": "negative"}, "relevance": 0.531102, "count": 1}, {"text": "AbbVie Inc.", "sentiment": {"score": -0.856525, "label": "negative"}, "relevance": 0.530154, "count": 1}, {"text": "diet", "sentiment": {"score": -0.429369, "label": "negative"}, "relevance": 0.529455, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527597, "count": 1}, {"text": "disease type", "sentiment": {"score": -0.849561, "label": "negative"}, "relevance": 0.527588, "count": 1}, {"text": "prevalence", "sentiment": {"score": -0.429369, "label": "negative"}, "relevance": 0.52726, "count": 1}, {"text": "South America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525636, "count": 1}, {"text": "route of administration", "sentiment": {"score": -0.849561, "label": "negative"}, "relevance": 0.525538, "count": 1}, {"text": "Segmentation", "sentiment": {"score": -0.849561, "label": "negative"}, "relevance": 0.524615, "count": 2}, {"text": "request", "sentiment": {"score": -0.856525, "label": "negative"}, "relevance": 0.522836, "count": 1}, {"text": "sample", "sentiment": {"score": -0.856525, "label": "negative"}, "relevance": 0.522694, "count": 1}, {"text": "AstraZeneca", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521068, "count": 1}, {"text": "Proton Pump Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520031, "count": 1}, {"text": "stress", "sentiment": {"score": -0.607916, "label": "negative"}, "relevance": 0.519547, "count": 1}, {"text": "basis of disease type", "sentiment": {"score": -0.959026, "label": "negative"}, "relevance": 0.519285, "count": 1}, {"text": "reports", "sentiment": {"score": -0.607916, "label": "negative"}, "relevance": 0.51918, "count": 1}, {"text": "market growth", "sentiment": {"score": -0.856525, "label": "negative"}, "relevance": 0.519029, "count": 1}, {"text": "com", "sentiment": {"score": -0.74902, "label": "negative"}, "relevance": 0.518967, "count": 2}, {"text": "Acid Neutralizers", "sentiment": {"score": -0.86354, "label": "negative"}, "relevance": 0.518854, "count": 2}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518448, "count": 2}]}, "extracted_metadata": {"sha1": "5baddc57bdd876752c84b8db7fef965083406ca4", "filename": "1542878395223.zip-d672821799978dbf56ef0e606f962208.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/sample_request/583", "https://www.marketresearchfuture.com/reports/americas-gastrointestinal-drugs-market-583"], "title": "Gastrointestinal Drugs Market Trend in America 2018 to 2023 | Perceive Accruals USD 59.3 Bn | Healthy Evolving Growth Rate | MarketResearchFuture.com", "forum_title": "openPR.com - New Public Relations: Business, Economy, Finances, Banking & Insurance"}, {"id": "x-I5ennPR8UuOzxoUMzAWz7OQNIzz93ldgYAIfzNImwhgxjI7hIQVGxkFBn_Hsxc", "result_metadata": {"score": 34.953403}, "author": "euroinvestor.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.935718, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997761, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.832988, "count": 1}]}, "crawl_date": "2018-11-22T14:53:27Z", "url": "http://www.euroinvestor.com/news/2018/11/22/form-83-takeda-pharmaceutical-co-ltd/13933820", "host": "euroinvestor.com", "text": "HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd PR Newswire London, November 22 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \u201cCode\u201d) 1.", "country": "DK", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-22T13:59:00+01:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.837187, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.667028, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.641718, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.562461, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.554035, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.534853, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jonathan Brown", "relevance": 0.515571, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.51527, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.505529, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.496436, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.496436, "type": "Quantity"}], "sentiment": {"document": {"score": 0.564914, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.957787, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.518642, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.500134, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.491666, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Futures contract", "relevance": 0.463776, "dbpedia_resource": "http://dbpedia.org/resource/Futures_contract"}, {"text": "Contract", "relevance": 0.449168, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.426837, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Put option", "relevance": 0.419532, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.409838, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Security", "relevance": 0.38423, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Unit type", "relevance": 0.372477, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Stock", "relevance": 0.37129, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.366125, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Option contract", "relevance": 0.36191, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Security", "relevance": 0.346012, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.343819, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.33938, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Moneyness", "relevance": 0.338737, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.936732, "label": "/real estate/buying and selling homes"}, {"score": 0.876641, "label": "/finance/financial news"}, {"score": 0.798463, "label": "/finance/investing/funds"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [404, 409], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [382, 385], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: Ordinary (ISIN: JP3463 4) Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 100 0.000 0 0.000 (2) Cash-settled derivatives: 8,454,400 1.078 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 100 0.000 8,454,400 1.078 All interests and all short positions should be disclosed.", "score": 0.531913, "arguments": [{"text": "Number\n%\nNumber\n%", "location": [1771, 1788], "entities": [{"type": "Organization", "text": "Number\n%\nNumber\n%", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Interests\nShort", "location": [1745, 1760], "entities": [{"type": "Organization", "text": "Interests\nShort", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit Ordinary Total Return Swap Increasing a short position 400,000 USD 38.3152 (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.787391, "arguments": [{"text": "i", "location": [3358, 3359], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3361, 3368], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3958, 3963], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3968, 3972], "entities": [{"type": "Organization", "text": "Price per unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4332, 4338], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4349, 4356], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 22 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [5210, 5216], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5224, 5228], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5291, 5315], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5283, 5288], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5570, 5594], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5562, 5567], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5626, 5631], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5645, 5672], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.692948, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.682164, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.661471, "count": 1}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.632876, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.617134, "count": 1}, {"text": "HBK Investments LP", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.585056, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.582462, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.748609, "label": "positive"}, "relevance": 0.580403, "count": 4}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.571573, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571132, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564155, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.54058, "label": "positive"}, "relevance": 0.561629, "count": 2}, {"text": "short positions", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.555955, "count": 3}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.54725, "count": 1}, {"text": "telephone number", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.546984, "count": 1}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.545602, "count": 3}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.543787, "count": 1}, {"text": "options", "sentiment": {"score": 0.688082, "label": "positive"}, "relevance": 0.543576, "count": 4}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.542913, "count": 2}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.542595, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.538177, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.538177, "count": 1}, {"text": "Code", "sentiment": {"score": -0.592735, "mixed": "1", "label": "negative"}, "relevance": 0.537681, "count": 3}, {"text": "Takeover Code", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.537217, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536633, "count": 1}, {"text": "Cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534349, "count": 2}, {"text": "Owner", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.533587, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53176, "count": 1}, {"text": "Form", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.531615, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.531615, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.531177, "count": 4}, {"text": "person", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.530933, "count": 4}, {"text": "arrangements", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.530784, "count": 3}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.530134, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.529801, "count": 1}, {"text": "Stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529683, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.529159, "count": 1}, {"text": "HBK Investments L.P.", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.528848, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.528673, "count": 2}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.528631, "count": 2}, {"text": "agreement", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.528435, "count": 2}, {"text": "Rule", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.52743, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527326, "count": 2}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.526558, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526135, "count": 1}, {"text": "understandings", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.525846, "count": 3}, {"text": "Number", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.52565, "count": 2}, {"text": "Purchases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525572, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524953, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.523061, "count": 1}]}, "extracted_metadata": {"sha1": "94c3379d392e3e0bd3b2686987a48558b17f53d7", "filename": "1542898407497.zip-413f858f997935ef98fa41934684ecac.xml", "file_type": "json"}, "external_links": ["https://www.thetakeoverpanel.org.uk/", "https://www.xmlnews.org/ns/"], "title": "Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "Latest Financial News, Stock News, Forex News and Commodity Market News - Euroinvestor"}, {"id": "brogQmPPf6Y7AanXGs6HdK0Mw5_9IgqaVg1GUMEv7QXHMU90aBSTZlkCwGzPc754", "result_metadata": {"score": 34.87469}, "author": "euroinvestor.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.935718, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997761, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.832988, "count": 1}]}, "crawl_date": "2018-11-22T14:49:19Z", "url": "https://www.euroinvestor.com/news/2018/11/22/form-83-takeda-pharmaceutical-co-ltd/13933820", "host": "euroinvestor.com", "text": "HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd PR Newswire London, November 22 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \u201cCode\u201d) 1.", "country": "DK", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-22T13:59:00+01:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.836616, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.666661, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.641299, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.562434, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.553954, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.534866, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jonathan Brown", "relevance": 0.515473, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.515213, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.505527, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.496404, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.496404, "type": "Quantity"}], "sentiment": {"document": {"score": 0.564914, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.956601, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.517162, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.49876, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.489842, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Futures contract", "relevance": 0.461711, "dbpedia_resource": "http://dbpedia.org/resource/Futures_contract"}, {"text": "Contract", "relevance": 0.448096, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.425662, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Put option", "relevance": 0.418425, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.408816, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Security", "relevance": 0.384128, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Unit type", "relevance": 0.372464, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Stock", "relevance": 0.370377, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.365385, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Option contract", "relevance": 0.361327, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Security", "relevance": 0.345305, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.342997, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.339365, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Moneyness", "relevance": 0.338725, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.938437, "label": "/real estate/buying and selling homes"}, {"score": 0.877968, "label": "/finance/financial news"}, {"score": 0.797206, "label": "/finance/investing/funds"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [404, 409], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [382, 385], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: Ordinary (ISIN: JP3463 4) Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 100 0.000 0 0.000 (2) Cash-settled derivatives: 8,454,400 1.078 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 100 0.000 8,454,400 1.078 All interests and all short positions should be disclosed.", "score": 0.531913, "arguments": [{"text": "Number\n%\nNumber\n%", "location": [1771, 1788], "entities": [{"type": "Organization", "text": "Number\n%\nNumber\n%", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Interests\nShort", "location": [1745, 1760], "entities": [{"type": "Organization", "text": "Interests\nShort", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit Ordinary Total Return Swap Increasing a short position 400,000 USD 38.3152 (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.787391, "arguments": [{"text": "i", "location": [3358, 3359], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3361, 3368], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3958, 3963], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3968, 3972], "entities": [{"type": "Organization", "text": "Price per unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4332, 4338], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4349, 4356], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 22 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [5237, 5243], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5251, 5255], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5318, 5342], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5310, 5315], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5597, 5621], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5589, 5594], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5653, 5658], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5672, 5699], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.690999, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.680325, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.660402, "count": 1}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.632799, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.615613, "count": 1}, {"text": "HBK Investments LP", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.583992, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.580872, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.579348, "count": 3}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.571684, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570307, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563003, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.54058, "label": "positive"}, "relevance": 0.561043, "count": 2}, {"text": "short positions", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.55558, "count": 3}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.546832, "count": 1}, {"text": "telephone number", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.546602, "count": 1}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.545194, "count": 3}, {"text": "options", "sentiment": {"score": 0.688082, "label": "positive"}, "relevance": 0.543108, "count": 4}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.543033, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.542136, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.542136, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.542115, "count": 2}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.541934, "count": 2}, {"text": "Code", "sentiment": {"score": -0.592735, "mixed": "1", "label": "negative"}, "relevance": 0.537321, "count": 3}, {"text": "Takeover Code", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.536588, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536078, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.534825, "count": 1}, {"text": "Cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534061, "count": 2}, {"text": "Owner", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.533272, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531429, "count": 1}, {"text": "Form", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.531364, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.531364, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.530879, "count": 4}, {"text": "person", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.530636, "count": 4}, {"text": "arrangements", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.530459, "count": 3}, {"text": "Stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52952, "count": 2}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.529447, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": 0.423193, "label": "positive"}, "relevance": 0.528842, "count": 1}, {"text": "HBK Investments L.P.", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.528294, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.528113, "count": 2}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.528073, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.527792, "count": 2}, {"text": "Rule", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.527168, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527137, "count": 2}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.526108, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525876, "count": 1}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.5256, "count": 1}, {"text": "understandings", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.525552, "count": 3}, {"text": "Number", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.525425, "count": 2}, {"text": "Purchases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525305, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524715, "count": 1}]}, "extracted_metadata": {"sha1": "52c227dc34f4d595598c38cfc5f4a1a6e3d93528", "filename": "1542898159040.zip-cf5c82b621ef3d0149e29c8c93e12287.xml", "file_type": "json"}, "external_links": ["https://www.thetakeoverpanel.org.uk/", "https://www.xmlnews.org/ns/"], "title": "Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "Latest Financial News, Stock News, Forex News and Commodity Market News - Euroinvestor"}, {"id": "e_PeO5qt9fqYaWgqf7s0_FvUzLaxbmI3i0hacVmcn64SwrEIxNGB6VOZHgyaiVi_", "result_metadata": {"score": 33.359486}, "author": "Ankush Nikam", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Diseases and disorders", "relevance": 0.856964, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}], "categories": [{"score": 0.995062, "label": "/health and fitness/disease"}], "relations": [], "keywords": [{"text": "Fabry Disease Global Trends", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999756, "count": 1}, {"text": "Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.801703, "count": 1}, {"text": "Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.759902, "count": 1}]}, "crawl_date": "2018-11-21T19:55:31Z", "url": "https://www.findmarketresearch.org/2018/11/fabry-disease-market-global-trends-analysis-and-forecast-2026/", "host": "findmarketresearch.org", "text": "Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T09:36:00+05:00", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.736695, "label": "negative"}, "text": "fabry disease", "relevance": 0.895924, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}, {"count": 1, "sentiment": {"score": -0.576522, "label": "negative"}, "text": "Fabry diseaseis", "relevance": 0.351688, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.786549, "label": "negative"}, "text": "APAC", "relevance": 0.147669, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.708726, "label": "negative"}, "text": "multiple organ failure", "relevance": 0.11985, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Multiple organ dysfunction syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_organ_dysfunction_syndrome"}}, {"count": 1, "sentiment": {"score": -0.581545, "label": "negative"}, "text": "Novartis Pharmaceuticals", "relevance": 0.117222, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.11558, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.109324, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva pharmaceutical Industries Ltd.", "relevance": 0.10663, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.1029, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi-Aventis LLC", "relevance": 0.101427, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.30305, "label": "negative"}, "text": "Gene", "relevance": 0.101175, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.100447, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.100318, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.0979442, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.428601, "label": "negative"}, "text": "Neuraltus Pharmaceuticals", "relevance": 0.0965181, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genzyme Corporation", "relevance": 0.095875, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"count": 1, "sentiment": {"score": 0.26394, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.0935097, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.0934038, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0922185, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America", "relevance": 0.0918692, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0.258488, "label": "positive"}, "text": "Western Europe", "relevance": 0.0904136, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.0855438, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merc & Co., Inc.", "relevance": 0.0843839, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "iBio, Inc.", "relevance": 0.0827811, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.0817953, "type": "Company"}], "sentiment": {"document": {"score": -0.780207, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Fabry", "keywords": [{"text": "Fabry"}], "entities": [{"type": "Person", "text": "Fabry diseaseis"}]}, "sentence": "Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency.", "object": {"text": "also known as Anderson-Fabry disease and alpha-galactosidase A deficiency", "keywords": [{"text": "Anderson-Fabry disease"}, {"text": "deficiency"}]}, "action": {"verb": {"text": "diseaseis", "tense": "present"}, "text": "diseaseis", "normalized": "diseaseis"}}, {"subject": {"text": "Fabry diseaseis", "keywords": [{"text": "Fabry diseaseis"}], "entities": [{"type": "Person", "text": "Fabry diseaseis"}]}, "sentence": "Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency.", "object": {"text": "as Anderson-Fabry disease and alpha-galactosidase A deficiency", "keywords": [{"text": "deficiency"}, {"text": "Anderson-Fabry disease"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "It"}, "sentence": " It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme", "keywords": [{"text": "lipid metabolism"}, {"text": "rare genetic disorder"}, {"text": "deficient activity"}, {"text": "enzyme"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme", "keywords": [{"text": "deficient activity"}, {"text": "enzyme"}, {"text": "alpha-galactosidase"}]}, "sentence": " It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "lipid metabolism", "keywords": [{"text": "lipid metabolism"}]}, "action": {"verb": {"text": "result", "tense": "present"}, "text": "resulting", "normalized": "result"}}, {"subject": {"text": "by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme", "keywords": [{"text": "alterations"}, {"text": "enzyme"}, {"text": "genes"}, {"text": "cells"}]}, "sentence": " The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "The deficiency of the enzyme", "keywords": [{"text": "deficiency"}, {"text": "enzyme"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "the alterations in the genes", "keywords": [{"text": "alterations"}, {"text": "genes"}]}, "sentence": " The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "the cells", "keywords": [{"text": "cells"}]}, "action": {"verb": {"text": "instruct", "tense": "present"}, "text": "instructs", "normalized": "instruct"}}, {"subject": {"text": "the cells", "keywords": [{"text": "cells"}]}, "sentence": " The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "alpha-galactosidase", "keywords": [{"text": "alpha-galactosidase"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "to make", "normalized": "to make"}}, {"subject": {"text": "Fabry disease", "keywords": [{"text": "Fabry disease"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "sentence": " Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "object": {"text": "known to cause variety of systemic symptoms and complications, one of them being metabolic disorders", "keywords": [{"text": "systemic symptoms"}, {"text": "metabolic disorders"}, {"text": "complications"}, {"text": "variety"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Fabry disease", "keywords": [{"text": "Fabry disease"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "sentence": " Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "object": {"text": "to cause variety of systemic symptoms and complications, one of them being metabolic disorders", "keywords": [{"text": "systemic symptoms"}, {"text": "metabolic disorders"}, {"text": "complications"}, {"text": "variety"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "The metabolism of sphingolipids", "keywords": [{"text": "metabolism"}, {"text": "sphingolipids"}]}, "sentence": " The metabolism of sphingolipids is minimized, in fabry disease which results in the multiple organ failure and death.", "object": {"text": "minimized, in fabry disease which results in the multiple organ failure and death", "keywords": [{"text": "multiple organ failure"}, {"text": "fabry disease"}, {"text": "death"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}, {"type": "HealthCondition", "text": "multiple organ failure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Multiple organ dysfunction syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_organ_dysfunction_syndrome"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "A enzyme, glycolipid called Gb3", "keywords": [{"text": "glycolipid"}, {"text": "enzyme"}, {"text": "Gb3"}]}, "sentence": " Owing to the deficiency of alpha galactosidase A enzyme, glycolipid called Gb3 accumulates in the blood vessels and other organs and thus results in formation of blockage or clots that leads to malfunctioning of the system.", "action": {"verb": {"text": "accumulate", "tense": "present"}, "text": "accumulates", "normalized": "accumulate"}}, {"subject": {"text": "Drivers and Restraints \u2013 The major drivers that drive the fabry disease market growth", "keywords": [{"text": "fabry disease market"}, {"text": "Restraints"}, {"text": "major drivers"}, {"text": "growth"}]}, "sentence": " Fabry Disease Market: Drivers and Restraints \u2013 The major drivers that drive the fabry disease market growth are extensive R&D activities, adoption of advanced technologies in the research practices.", "object": {"text": "extensive R&D activities, adoption of advanced technologies in the research practices", "keywords": [{"text": "extensive R&D activities"}, {"text": "advanced technologies"}, {"text": "research practices"}, {"text": "adoption"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "complications in physiological systems, such as cardiac system, urinary system and others", "keywords": [{"text": "physiological systems"}, {"text": "complications"}], "entities": []}, "sentence": " Due to hereditary nature and severity of the disease, complications in physiological systems, such as cardiac system, urinary system and others are expected to increase the demand for trustworthy treatment.", "object": {"text": "the demand for trustworthy treatment", "keywords": [{"text": "trustworthy treatment"}, {"text": "demand"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "are expected to increase", "normalized": "be expect to increase"}}, {"subject": {"text": "Extensive R&D practices", "keywords": [{"text": "Extensive R&D practices"}]}, "sentence": " Extensive R&D practices is one of the valuable drivers of the market.", "object": {"text": "one of the valuable drivers of the market", "keywords": [{"text": "valuable drivers"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "various therapeutic products, such as, PRX-102, JR-051, NP-003, GC-1119 and others,", "keywords": [{"text": "various therapeutic products"}, {"text": "JR-051"}, {"text": "NP-003"}, {"text": "GC-1119"}]}, "sentence": " Due to this, various therapeutic products, such as, PRX-102, JR-051, NP-003, GC-1119 and others, are under pipeline studies.", "object": {"text": "under pipeline studies", "keywords": [{"text": "pipeline studies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "technological limitations in certain region of the world", "keywords": [{"text": "technological limitations"}, {"text": "certain region"}, {"text": "world"}]}, "sentence": " However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic sciences, technological limitations in certain region of the world are some of the restraining factors that may affect the growth of the fabry disease market.", "object": {"text": "some of the restraining factors that may affect the growth of the fabry disease market", "keywords": [{"text": "fabry disease market"}, {"text": "restraining factors"}, {"text": "growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "some of the restraining factors", "keywords": [{"text": "restraining factors"}]}, "sentence": " However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic sciences, technological limitations in certain region of the world are some of the restraining factors that may affect the growth of the fabry disease market.", "object": {"text": "the growth of the fabry disease market", "keywords": [{"text": "fabry disease market"}, {"text": "growth"}]}, "action": {"verb": {"text": "affect", "tense": "future"}, "text": "may affect", "normalized": "may affect"}}, {"subject": {"text": "Segmentation \u2013 The global fabry disease market", "keywords": [{"text": "global fabry disease"}, {"text": "Segmentation"}]}, "sentence": " Fabry Disease Market: Segmentation \u2013 The global fabry disease market has been classified on the basis of treatment, end use and geography.", "object": {"text": "been classified on the basis of treatment, end use and geography", "keywords": [{"text": "basis"}, {"text": "geography"}, {"text": "treatment"}, {"text": "end"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Segmentation \u2013 The global fabry disease market", "keywords": [{"text": "global fabry disease"}, {"text": "Segmentation"}]}, "sentence": " Fabry Disease Market: Segmentation \u2013 The global fabry disease market has been classified on the basis of treatment, end use and geography.", "object": {"text": "classified on the basis of treatment, end use and geography", "keywords": [{"text": "basis"}, {"text": "geography"}, {"text": "treatment"}, {"text": "end"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Segmentation \u2013 The global fabry disease market", "keywords": [{"text": "global fabry disease"}, {"text": "Segmentation"}]}, "sentence": " Fabry Disease Market: Segmentation \u2013 The global fabry disease market has been classified on the basis of treatment, end use and geography.", "object": {"text": "on the basis of treatment, end use and geography", "keywords": [{"text": "basis"}, {"text": "geography"}, {"text": "treatment"}, {"text": "end"}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "has been classified", "normalized": "have be classify"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs, Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics.", "object": {"text": "divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs", "keywords": [{"text": "Enzyme replacement therapy"}, {"text": "agalsidase alpha"}, {"text": "Pharmaceutical formulations"}, {"text": "Gene therapy"}], "entities": [{"type": "Person", "text": "Gene"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs, Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics.", "object": {"text": "into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs, Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics", "keywords": [{"text": "Enzyme replacement therapy"}, {"text": "global fabry disease"}, {"text": "end user type"}, {"text": "agalsidase alpha"}], "entities": [{"type": "Person", "text": "Gene"}]}, "action": {"verb": {"text": "divide", "tense": "past"}, "text": "is divided", "normalized": "be divide"}}, {"subject": {"text": "NSAIDs", "keywords": [{"text": "NSAIDs"}]}, "sentence": " Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs, Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics.", "object": {"text": "on end user type", "keywords": [{"text": "end user type"}], "entities": []}, "action": {"verb": {"text": "Based", "tense": "past"}, "text": "Based", "normalized": "Based"}}, {"subject": {"text": "Overview \u2013 The enzyme replacement therapy", "keywords": [{"text": "enzyme replacement therapy"}, {"text": "Overview"}]}, "sentence": " Fabry Disease Market: Overview \u2013 The enzyme replacement therapy is designed to provide enzyme to the patients suffering from enzyme deficiency.", "object": {"text": "enzyme", "keywords": [{"text": "enzyme"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "is designed to provide", "normalized": "be design to provide"}}, {"subject": {"text": "enzyme to the patients", "keywords": [{"text": "enzyme"}, {"text": "patients"}]}, "sentence": " Fabry Disease Market: Overview \u2013 The enzyme replacement therapy is designed to provide enzyme to the patients suffering from enzyme deficiency.", "object": {"text": "from enzyme deficiency", "keywords": [{"text": "enzyme deficiency"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "Enzyme replacement therapy", "keywords": [{"text": "Enzyme replacement therapy"}]}, "sentence": " Enzyme replacement therapy is the most expensive and unaffordable treatment among the treatments for fabry disease, hence the market for enzyme replacement therapy is expected to register moderate growth in overall fabry disease market.", "object": {"text": "the most expensive and unaffordable treatment among the treatments for fabry disease", "keywords": [{"text": "fabry disease"}, {"text": "unaffordable treatment"}, {"text": "treatments"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "enzyme replacement therapy", "keywords": [{"text": "enzyme replacement therapy"}]}, "sentence": " Enzyme replacement therapy is the most expensive and unaffordable treatment among the treatments for fabry disease, hence the market for enzyme replacement therapy is expected to register moderate growth in overall fabry disease market.", "object": {"text": "moderate growth", "keywords": [{"text": "moderate growth"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "The analgesics, anticonvulsants and NSAIDs", "keywords": [{"text": "analgesics"}, {"text": "NSAIDs"}, {"text": "anticonvulsants"}]}, "sentence": " The analgesics, anticonvulsants and NSAIDs are generally known for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market.", "object": {"text": "for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market", "keywords": [{"text": "fabry disease"}, {"text": "pain"}, {"text": "treatment"}, {"text": "symptoms"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "are generally known", "normalized": "be generally know"}}, {"subject": {"text": "Regional Overview \u2013 Geographically, the global fabry disease market", "keywords": [{"text": "global fabry disease"}, {"text": "Regional Overview"}]}, "sentence": " Fabry Disease Market: Regional Overview \u2013 Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America", "keywords": [{"text": "Middle East"}, {"text": "Western Europe"}, {"text": "Eastern Europe"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Fabry Disease Market: Regional Overview \u2013 Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe", "keywords": [{"text": "lucrative region"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "is classified", "normalized": "be classify"}}, {"subject": {"text": "Middle East and Africa.North America", "keywords": [{"text": "Middle East"}, {"text": "Africa.North America"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Fabry Disease Market: Regional Overview \u2013 Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "to be the most lucrative region", "keywords": [{"text": "lucrative region"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "by Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Fabry Disease Market: Regional Overview \u2013 Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "the affordability of the treatment", "keywords": [{"text": "affordability"}, {"text": "treatment"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "The rare incidences in APAC and MEA countries", "keywords": [{"text": "rare incidences"}, {"text": "MEA countries"}, {"text": "APAC"}], "entities": []}, "sentence": " The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "object": {"text": "the growth of fabry disease market in these regions", "keywords": [{"text": "fabry disease market"}, {"text": "regions"}]}, "action": {"verb": {"text": "limit", "tense": "future"}, "text": "are expected to limit", "normalized": "be expect to limit"}}, {"subject": {"text": "Key Players \u2013 The major players", "keywords": [{"text": "Key Players"}, {"text": "major players"}]}, "sentence": " Fabry Disease Market: Key Players \u2013 The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc.", "object": {"text": "in development of new medications", "keywords": [{"text": "new medications"}, {"text": "development"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc", "keywords": [{"text": "GlaxoSmithKline plc"}, {"text": "Sanofi-Aventis LLC"}, {"text": "Genzyme Corporation"}, {"text": "Neuraltus Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Sanofi-Aventis LLC"}, {"type": "Company", "text": "iBio, Inc."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Genzyme Corporation", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"type": "Company", "text": "Neuraltus Pharmaceuticals"}]}, "sentence": " Fabry Disease Market: Key Players \u2013 The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc.", "object": {"text": "new medications", "keywords": [{"text": "new medications"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Some of the existing key players in the global fabry disease market", "keywords": [{"text": "global fabry disease"}, {"text": "key players"}]}, "sentence": " Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd.", "object": {"text": "Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Teva pharmaceutical Industries"}, {"text": "Novartis Pharmaceuticals"}, {"text": "Pfizer Inc."}], "entities": [{"type": "Company", "text": "Novartis Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Merc & Co., Inc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Teva pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Fabry disease", "relevance": 0.97566, "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}, {"text": "Enzyme replacement therapy", "relevance": 0.9683, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_replacement_therapy"}, {"text": "Bristol-Myers Squibb", "relevance": 0.838465, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.757688, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Therapy", "relevance": 0.650208, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Clopidogrel", "relevance": 0.632645, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Metabolism", "relevance": 0.615073, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Sphingolipidoses", "relevance": 0.600743, "dbpedia_resource": "http://dbpedia.org/resource/Sphingolipidoses"}, {"text": "Medicine", "relevance": 0.600728, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.993306, "label": "/health and fitness/disease"}, {"score": 0.886854, "label": "/health and fitness/disorders"}, {"score": 0.801835, "label": "/health and fitness/therapy"}], "relations": [{"type": "hasAttribute", "sentence": "Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "score": 0.469575, "arguments": [{"text": "Fabry", "location": [370, 375], "entities": [{"type": "Person", "text": "Fabry diseaseis"}]}, {"text": "metabolic disorders", "location": [468, 487], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "hasAttribute", "sentence": "Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "score": 0.782799, "arguments": [{"text": "them", "location": [457, 461], "entities": [{"type": "Person", "text": "them"}]}, {"text": "metabolic disorders", "location": [468, 487], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "locatedAt", "sentence": "However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic sciences, technological limitations in certain region of the world are some of the restraining factors that may affect the growth of the fabry disease market.", "score": 0.243329, "arguments": [{"text": "region", "location": [1571, 1577], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}, {"text": "world", "location": [1585, 1590], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs, Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics.", "score": 0.515152, "arguments": [{"text": "Anticonvulsants", "location": [2012, 2027], "entities": [{"type": "Person", "text": "Anticonvulsants"}]}, {"text": "NSAIDs", "location": [2029, 2035], "entities": [{"type": "Person", "text": "NSAIDs"}]}]}, {"type": "hasAttribute", "sentence": "The analgesics, anticonvulsants and NSAIDs are generally known for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market.", "score": 0.518347, "arguments": [{"text": "NSAIDs", "location": [2649, 2655], "entities": [{"type": "Person", "text": "NSAIDs"}]}, {"text": "disease hence", "location": [2743, 2756], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "locatedAt", "sentence": "Fabry Disease Market: Regional Overview - Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "score": 0.513586, "arguments": [{"text": "Eastern Europe", "location": [2965, 2979], "entities": [{"type": "GeopoliticalEntity", "text": "Eastern Europe"}]}, {"text": "APAC", "location": [2981, 2985], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}]}, {"type": "locatedAt", "sentence": "Fabry Disease Market: Regional Overview - Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "score": 0.72389, "arguments": [{"text": "APAC", "location": [2981, 2985], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}, {"text": "Japan", "location": [2987, 2992], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "score": 0.80263, "arguments": [{"text": "countries", "location": [3176, 3185], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "APAC", "location": [3163, 3167], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}]}, {"type": "partOf", "sentence": "The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "score": 0.651857, "arguments": [{"text": "MEA", "location": [3172, 3175], "entities": [{"type": "Organization", "text": "MEA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "countries", "location": [3176, 3185], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "Anderson-Fabry disease", "sentiment": {"score": -0.563953, "label": "negative"}, "relevance": 0.779346, "count": 1}, {"text": "Fabry diseaseis", "sentiment": {"score": -0.563953, "label": "negative"}, "relevance": 0.752983, "count": 1}, {"text": "Fabry Disease Market", "sentiment": {"score": -0.904862, "label": "negative"}, "relevance": 0.738475, "count": 4}, {"text": "Enzyme replacement therapy", "sentiment": {"score": -0.856464, "label": "negative"}, "relevance": 0.657923, "count": 2}, {"text": "Fabry disease", "sentiment": {"score": -0.927153, "label": "negative"}, "relevance": 0.642156, "count": 1}, {"text": "fabry disease market growth", "sentiment": {"score": -0.936718, "label": "negative"}, "relevance": 0.634802, "count": 1}, {"text": "rare genetic disorder of lipid metabolism", "sentiment": {"score": -0.737951, "label": "negative"}, "relevance": 0.624781, "count": 1}, {"text": "disease", "sentiment": {"score": -0.80553, "label": "negative"}, "relevance": 0.606793, "count": 3}, {"text": "North America", "sentiment": {"score": -0.795253, "label": "negative"}, "relevance": 0.589455, "count": 2}, {"text": "global fabry disease market", "sentiment": {"score": -0.857697, "label": "negative"}, "relevance": 0.583106, "count": 5}, {"text": "enzyme", "sentiment": {"score": -0.860625, "label": "negative"}, "relevance": 0.582698, "count": 4}, {"text": "enzyme replacement therapy", "sentiment": {"score": -0.906062, "label": "negative"}, "relevance": 0.569536, "count": 2}, {"text": "Gene therapy", "sentiment": {"score": -0.869597, "label": "negative"}, "relevance": 0.56946, "count": 1}, {"text": "Western Europe", "sentiment": {"score": -0.795253, "label": "negative"}, "relevance": 0.566656, "count": 1}, {"text": "trustworthy treatment", "sentiment": {"score": 0.260084, "mixed": "1", "label": "positive"}, "relevance": 0.566254, "count": 1}, {"text": "rare incidence rate", "sentiment": {"score": -0.89592, "label": "negative"}, "relevance": 0.565574, "count": 1}, {"text": "growth of the fabry disease market", "sentiment": {"score": -0.899892, "label": "negative"}, "relevance": 0.558863, "count": 1}, {"text": "alpha-galactosidase", "sentiment": {"score": -0.563953, "label": "negative"}, "relevance": 0.557437, "count": 1}, {"text": "valuable drivers of the market", "sentiment": {"score": 0.731955, "label": "positive"}, "relevance": 0.548902, "count": 1}, {"text": "Latin America", "sentiment": {"score": -0.795253, "label": "negative"}, "relevance": 0.547604, "count": 1}, {"text": "major players", "sentiment": {"score": -0.770219, "label": "negative"}, "relevance": 0.547277, "count": 1}, {"text": "Key Players", "sentiment": {"score": -0.770219, "label": "negative"}, "relevance": 0.545266, "count": 1}, {"text": "Eastern Europe", "sentiment": {"score": -0.795253, "label": "negative"}, "relevance": 0.543875, "count": 1}, {"text": "Middle East", "sentiment": {"score": -0.795253, "label": "negative"}, "relevance": 0.542636, "count": 1}, {"text": "treatment", "sentiment": {"score": -0.869597, "label": "negative"}, "relevance": 0.538476, "count": 2}, {"text": "deficiency of the enzyme", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537405, "count": 1}, {"text": "regions", "sentiment": {"score": -0.782815, "label": "negative"}, "relevance": 0.536337, "count": 2}, {"text": "analgesics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534279, "count": 1}, {"text": "Analgesics", "sentiment": {"score": -0.869597, "label": "negative"}, "relevance": 0.534279, "count": 1}, {"text": "region of the world", "sentiment": {"score": -0.89592, "label": "negative"}, "relevance": 0.529219, "count": 1}, {"text": "market", "sentiment": {"score": -0.803516, "label": "negative"}, "relevance": 0.528644, "count": 3}, {"text": "genes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527936, "count": 1}, {"text": "Drivers", "sentiment": {"score": -0.936718, "label": "negative"}, "relevance": 0.5279, "count": 1}, {"text": "APAC", "sentiment": {"score": -0.792597, "label": "negative"}, "relevance": 0.5273, "count": 2}, {"text": "blood vessels", "sentiment": {"score": -0.78699, "label": "negative"}, "relevance": 0.527267, "count": 1}, {"text": "NSAIDs", "sentiment": {"score": -0.869597, "label": "negative"}, "relevance": 0.5266, "count": 2}, {"text": "Overview", "sentiment": {"score": -0.95848, "label": "negative"}, "relevance": 0.52522, "count": 1}, {"text": "others", "sentiment": {"score": -0.668185, "label": "negative"}, "relevance": 0.525068, "count": 2}, {"text": "deficiency", "sentiment": {"score": -0.563953, "label": "negative"}, "relevance": 0.524498, "count": 1}, {"text": "system", "sentiment": {"score": -0.865593, "label": "negative"}, "relevance": 0.524362, "count": 1}, {"text": "Pharmaceutical formulations", "sentiment": {"score": -0.869597, "label": "negative"}, "relevance": 0.523762, "count": 1}, {"text": "results", "sentiment": {"score": -0.78699, "label": "negative"}, "relevance": 0.521564, "count": 2}, {"text": "metabolism", "sentiment": {"score": -0.841924, "label": "negative"}, "relevance": 0.520037, "count": 1}, {"text": "Europe", "sentiment": {"score": -0.790407, "label": "negative"}, "relevance": 0.519958, "count": 1}, {"text": "Inc.", "sentiment": {"score": -0.816202, "label": "negative"}, "relevance": 0.519719, "count": 3}, {"text": "growth", "sentiment": {"score": -0.790407, "label": "negative"}, "relevance": 0.519665, "count": 1}, {"text": "treatments", "sentiment": {"score": -0.841924, "label": "negative"}, "relevance": 0.519267, "count": 1}, {"text": "advancements", "sentiment": {"score": -0.89592, "label": "negative"}, "relevance": 0.517659, "count": 1}, {"text": "metabolic disorders", "sentiment": {"score": -0.927153, "label": "negative"}, "relevance": 0.517499, "count": 1}, {"text": "deficient activity of the alpha-galactosidase A", "sentiment": {"score": -0.737951, "label": "negative"}, "relevance": 0.517356, "count": 1}]}, "extracted_metadata": {"sha1": "fb220b7fcea7b77283e6ad94e19a07b64e019b7c", "filename": "1542830131751.zip-63406ff87a91dae6550cfc12f4d9915b.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/sample/rep-gb-1365", "https://www.futuremarketinsights.com/reports/fabry-disease-market"], "title": "Fabry Disease Global Trends, Analysis and Forecast 2026", "forum_title": "Research Insights | Find Market Research - Part 29"}, {"id": "uh5rcdsHcPZFObxfQwbYygpex8_fmvYHu0v-JSmhjC29AW0UR4cgJNKnBD50a-q4", "result_metadata": {"score": 33.177387}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.328886, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.900486, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Barclays", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.989818, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.947998, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.931092, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.054708, "count": 1}]}, "crawl_date": "2018-11-22T07:51:09Z", "url": "https://www.marketscreener.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-AMENDMENT-27647546/", "host": "marketscreener.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-22T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.765474, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.668549, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.621291, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.538529, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.520549, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.470149, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.428708, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.412473, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.412473, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.412473, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.412473, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,105,037 1.40%", "relevance": 0.412473, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,907,286 1.50%", "relevance": 0.412473, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,379,978 1.56%", "relevance": 0.412473, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,533,923 4.22%", "relevance": 0.412473, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,576,678 4.23%", "relevance": 0.412473, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.412473, "type": "Quantity"}], "sentiment": {"document": {"score": 0.605064, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)]", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,533,923 4.22% 33,576,678 4.23% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "33,533,923 4.22"}, {"type": "Quantity", "text": "33,576,678 4.23"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,105,037 1.40% 12,379,978 1.56% (2) Cash-settled derivatives: 11,907,286 1.50% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,533,923 4.22% 33,576,678 4.23% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,533,923 4.22% 33,576,678 4.23% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,533,923 4.22"}, {"type": "Quantity", "text": "33,576,678 4.23"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,105,037 1.40% 12,379,978 1.56% (2) Cash-settled derivatives: 11,907,286 1.50% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,533,923 4.22% 33,576,678 4.23% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 21 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 22 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 22 November 2018 07:25:06 UTC", "object": {"text": "06 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.968875, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.734901, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.683977, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.605871, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.498804, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.406785, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.391982, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.375439, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.341933, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.33117, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Contract", "relevance": 0.322658, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.318779, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "December", "relevance": 0.314971, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Barclays", "relevance": 0.311934, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Unit type", "relevance": 0.297755, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Japanese yen", "relevance": 0.290034, "dbpedia_resource": "http://dbpedia.org/resource/Japanese_yen"}], "categories": [{"score": 0.866221, "label": "/real estate/buying and selling homes"}, {"score": 0.807968, "label": "/finance/financial news"}, {"score": 0.782325, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "NPV Sale 3,800 4,314.9211 JPY Ordinary NPV Sale 4,300 4,308.0162 JPY Ordinary NPV Sale 4,700 4,323.0212 JPY Ordinary NPV Sale 5,000 4,313.1800 JPY Ordinary NPV Sale 5,100 4,316.0980 JPY Ordinary NPV Sale 5,700 4,301.9122 JPY Ordinary NPV Sale 7,300 4,293.3561 JPY Ordinary NPV Sale 9,600 4,302.5520 JPY Ordinary NPV Sale 15,200 4,329.0592 JPY Ordinary NPV Sale 68,200 4,314.5586 JPY Ordinary NPV Sale 403,800 4,309.8164 JPY Ordinary NPV Sale 443,800 4,314.2559 JPY Ordinary NPV Sale 712,700 4,314.1426 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 15,500 4,356.5643 JPY Ordinary NPV SWAP Short 600 4,306.3333 JPY Ordinary NPV SWAP Short 58,100 4,293.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [5423, 5424], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5426, 5433], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6397, 6403], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6414, 6421], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 21 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7323, 7329], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7337, 7341], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [7769, 7775], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7783, 7796], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7404, 7428], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7396, 7401], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9915, 9939], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9907, 9912], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7563, 7568], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7582, 7609], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10074, 10079], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10093, 10120], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7845, 7851], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7877, 7889], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181121005597/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 22 November 2018 and is solely responsible for the information contained herein.", "score": 0.979718, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10286, 10319], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [10320, 10329], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181121005597/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 22 November 2018 and is solely responsible for the information contained herein.", "score": 0.734225, "arguments": [{"text": "November 2018", "location": [10349, 10362], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [10320, 10329], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.75469, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.649411, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.631944, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.64284, "label": "positive"}, "relevance": 0.620663, "count": 4}, {"text": "Purchases", "sentiment": {"score": 0.641705, "mixed": "1", "label": "positive"}, "relevance": 0.595986, "count": 2}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.59508, "count": 12}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.593621, "count": 1}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.589243, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.415616, "mixed": "1", "label": "positive"}, "relevance": 0.583893, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.578036, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.576242, "count": 2}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.572693, "count": 2}, {"text": "options", "sentiment": {"score": 0.769049, "label": "positive"}, "relevance": 0.571401, "count": 4}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566331, "count": 1}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.565817, "count": 5}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.563582, "count": 3}, {"text": "Code", "sentiment": {"score": -0.439685, "mixed": "1", "label": "negative"}, "relevance": 0.558356, "count": 5}, {"text": "Details", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.552339, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549951, "count": 1}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.546524, "count": 1}, {"text": "Panel's Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54371, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.541324, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.36225, "mixed": "1", "label": "positive"}, "relevance": 0.540391, "count": 2}, {"text": "View source version", "sentiment": {"score": -0.481928, "label": "negative"}, "relevance": 0.536548, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.536449, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.535128, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.533681, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.533548, "count": 2}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533157, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.532455, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.532455, "count": 1}, {"text": "relevant Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.5321, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531544, "count": 1}, {"text": "relation", "sentiment": {"score": 0.659149, "label": "positive"}, "relevance": 0.531071, "count": 5}, {"text": "positions", "sentiment": {"score": 0.806498, "label": "positive"}, "relevance": 0.529869, "count": 2}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.529186, "count": 8}, {"text": "form", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.52899, "count": 1}, {"text": "FORM", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.52899, "count": 1}, {"text": "Sales", "sentiment": {"score": -0.575545, "label": "negative"}, "relevance": 0.527983, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527584, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52602, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.525278, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.524577, "count": 2}, {"text": "nature of the rights", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.524446, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.524323, "count": 2}, {"text": "option", "sentiment": {"score": 0.736995, "label": "positive"}, "relevance": 0.523946, "count": 4}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523119, "count": 3}, {"text": "Rule", "sentiment": {"score": -0.881961, "label": "negative"}, "relevance": 0.523013, "count": 2}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.522697, "count": 1}, {"text": "Class of Product Nature", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.521214, "count": 1}]}, "extracted_metadata": {"sha1": "4a954e79d9f67e2a85cdbb30b82136ce2f818b7d", "filename": "1542873069444.zip-371fe9c83e270b8d5b4910298a3793c1.xml", "file_type": "json"}, "external_links": ["https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51903365&newsitemid=20181121005597&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=4be6079359d6e2b4d3184cb290823742", "https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51903365&newsitemid=20181121005597&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=2&md5=e0410b8fe4646aee5f489de71c3abf20", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1209155", "http://www.publicnow.com/view/73994ED00559C78664CD6B362F063C16EAB0EFF0", "https://www.businesswire.com/news/home/20181121005597/en/"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD AMENDMENT | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}]}